<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>055 Pharmacology Ini-Cet 2022 - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}


    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / PYQs / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">57</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>
        let questionsData = [
  {
    "text": "The extent of drug absorption is represented by:",
    "choices": [
      {
        "id": 1,
        "text": "Tmax"
      },
      {
        "id": 2,
        "text": "Area under the curve"
      },
      {
        "id": 3,
        "text": "Cmax"
      },
      {
        "id": 4,
        "text": "t1/2"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>\u00a0</p>\n<p>Bioavailability of drug\u00a0injected intravenously is 100%, but it is lower\u00a0after oral ingestion because of\u00a0incomplete absorption and first-pass metabolism in the intestinal wall/liver.</p>\n<p>The image below shows the difference between the bioavailability of drugs injected intravenously(iv) and orally(PO). Note the area under the respective curves is shaded in red and blue colours which represent the absorption of the drug.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/faee105612ff4db99088f395111a460ex1280x1008.JPEG",
      "https://dhmbxeygs57ff.cloudfront.net/uploads/004ea54ec8dd43dab6444638a0d26247x1184x1162.PNG"
    ]
  },
  {
    "text": "Which of the following statement is correct regarding the given graph?",
    "choices": [
      {
        "id": 1,
        "text": "Drug 1 represents agonist and drug 2 represents inverse agonist"
      },
      {
        "id": 2,
        "text": "Drug 3 represents agonist and drug 4 represents inverse agonist"
      },
      {
        "id": 3,
        "text": "Drug  1 represents agonist and drug 4 represents inverse agonist"
      },
      {
        "id": 4,
        "text": "Drug 2 represents partial agonist and drug 3 represents inverse agonist"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The correct statement is <strong>Drug 1 represents agonist and drug 4 represents inverse agonist.</strong></p>\n<p><strong>Graph 1 </strong>represents the <strong>agonist: </strong>An agonist is an agent which initiates the <strong>normal</strong> <strong>physiological response</strong> when combined with a receptor.</p>\n<p>Example: Salbutamol is a beta-2 receptor agonist.</p>\n<p><strong>Graph 2</strong> represents a <strong>partial agonist</strong>: An agent which produces a <strong>submaximal or partial effect</strong> when combined with a receptor.</p>\n<p>Example: B<span class=\"ILfuVd\" lang=\"en\"><span class=\"hgKElc\">uprenorphine and butorphanol are partial agonists at opioid receptors. </span></span></p>\n<p><strong>Graph 3 </strong>represents the <strong>antagonist</strong>: An agent which blocks or reduces the action of an agonist on a receptor, but does not have any effect of its own.</p>\n<p>Example: N<span class=\"ILfuVd\" lang=\"en\"><span class=\"hgKElc\">altrexone and naloxone are antagonists at opioid receptors </span></span></p>\n<p><strong>Graph 4</strong> represents an<strong> inverse agonist</strong>: An agent which activates a receptor to produce an effect in the opposite direction to that of the agonist.</p>\n<p>Example: &beta;-Carboline is an inverse agonist at benzodiazepine site of GABA-A receptor.</p>\n<p>The image given below shows action of various types of selective receptor modulators.</p>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/bef9557aa4ee45d5ac653541181d4996.JPEG"
    ],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/8d7167c153aa42a5bdc0787fd454473ex1280x1252.JPEG"
    ]
  },
  {
    "text": "Which among the following drugs is the new FDA approved immune check point inhibitor for carcinoma endometrium?",
    "choices": [
      {
        "id": 1,
        "text": "Nivolumab"
      },
      {
        "id": 2,
        "text": "Pembrolizumab"
      },
      {
        "id": 3,
        "text": "Trastuzumab"
      },
      {
        "id": 4,
        "text": "Ipilimumab"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The new FDA-approved <strong>immune checkpoint inhibitor</strong> for carcinoma endometrium is <strong>pembrolizumab</strong>.</p>\n<p>Pembrolizumab acts by inhibiting programmed death receptor - 1 (<strong>PD-1</strong>) and was used for the treatment of&nbsp;<strong>advanced melanoma</strong>. Now, the FDA has&nbsp;approved the use of pembrolizumab for any cancer with mismatch repair (<strong>MMR</strong>) deficiency or high microsatellite instability (<strong>MSI-H</strong>).</p>\n<p>On March 21, 2022, the food and drug administration approved pembrolizumab, as a single agent, for patients with <strong>advanced endometrial carcinoma</strong> that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test.</p>\n<p>Other options:</p>\n<p>Option A:&nbsp;<strong>Nivolumab</strong> is an&nbsp;immune checkpoint inhibitor that acts by inhibiting programmed death receptor - 1 (<strong>PD-1</strong>) and is used for the treatment of&nbsp;<strong>advanced melanoma </strong>and<strong>&nbsp;</strong>relapsed/refractory<strong>&nbsp;classical Hodgkin lymphoma.</strong></p>\n<p>Option C:<strong>&nbsp; Trastuzumab&nbsp;</strong>is a monoclonal antibody that inhibits the <strong>HER2 receptor</strong>. It is used in the treatment of <strong>HER2-positive breast cancer</strong>.</p>\n<p>Option D:&nbsp;<strong>Ipilimumab</strong> is a monoclonal antibody that binds to cytotoxic T lymphocyte&ndash;associated Protein 4 (<strong>CTLA-4</strong>) and is approved for the treatment of late-stage <strong>melanoma</strong>.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following is not an immune checkpoint inhibitor?",
    "choices": [
      {
        "id": 1,
        "text": "Nivolumab"
      },
      {
        "id": 2,
        "text": "Pembrolizumab"
      },
      {
        "id": 3,
        "text": "Atezolimumab"
      },
      {
        "id": 4,
        "text": "Cetuximab"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Cetuximab</strong> is not&nbsp;an <strong>immune checkpoint inhibitor</strong>. Cetuximab is a monoclonal antibody against <strong>epidermal growth factor receptor(EGFR)</strong>. It is used for the treatment of <strong>colon cancer</strong> and head and neck squamous cell cancer.</p>\n<p>Other options.</p>\n<p>Option A:<strong> Nivolumab </strong>is an immune checkpoint inhibitor. It acts by inhibiting programmed death receptor - 1 (<strong>PD-1</strong>) and is used for the treatment of <strong>advanced melanoma</strong> and <strong>classical Hodgkin lymphoma.&nbsp;</strong></p>\n<p>Option B: <strong>Pembrolizumab</strong> is an immune checkpoint inhibitor. It acts by inhibiting programmed death receptor - 1 (<strong>PD-1</strong>) and is used for the treatment of <strong>advanced melanoma</strong>.&nbsp;In 2021, approval was granted for the treatment of patients with <strong>endometrial carcinoma</strong> that progressed after systemic treatment, in combination with <strong>lenvatinib</strong>.</p>\n<p>Option C: <strong>Atezolimumab</strong> is an immune checkpoint inhibitor. It acts by&nbsp;inhibiting programmed death-ligand - 1 (<strong>PDL-1</strong>) and is used for the treatment of <strong>non-small cell lung cancer</strong>.&nbsp;</p>\n<p>Important note:</p>\n<p>The FDA on&nbsp;<strong>May 2021</strong>&nbsp;approved the use of&nbsp;<strong>nivolumab</strong>&nbsp;in patients having completely resected <strong>esophageal or gastroesophageal junction cancers</strong>&nbsp;with residual pathologic disease who have received neoadjuvant chemoradiotherapy.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "NAPQI is the metabolite of which of the following drug toxicity?",
    "choices": [
      {
        "id": 1,
        "text": "Aspirin"
      },
      {
        "id": 2,
        "text": "Paracetamol"
      },
      {
        "id": 3,
        "text": "Diclofenac"
      },
      {
        "id": 4,
        "text": "Ketorolac"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>N-acetyl-p-benzoquinone imine</strong>&nbsp;(NAPQI) is a metabolite of <strong>paracetamol</strong> drug toxicity.&nbsp;</p>\n<p>Paracetamol is an analgesic and antipyretic with <strong>weak anti-inflammatory action</strong>. It is mainly metabolized&nbsp;in the <strong>liver</strong> by conjugation with <strong>glucuronic acid</strong> and sulfate and is excreted in the urine.</p>\n<p>At toxic doses, the glucuronide and sulfate conjugation pathway becomes <strong>saturated</strong>. The metabolites of paracetamol get converted into NAPQI. NAPQI is&nbsp;<strong>highly reactive</strong> and causes enzymatic dysfunction in the liver. Normally, minor amounts of NAPQI produced in our body are rapidly eliminated by conjugation with <strong>reduced glutathione(GSH)</strong> and then excreted into the urine.</p>\n<p>Therefore, paracetamol toxicity is treated with <strong>N-acetyl cysteine(NAC)</strong>, which <strong>replenishes GSH.&nbsp;</strong>NAC thereby helps in the excretion of NAPQI from the body. N-acetyl cysteine is an <strong>anti-oxidant</strong> and functions by detoxifying NAPQI.</p>\n<p>Paracetamol poisoning is the <strong>most common</strong> cause of liver failure necessitating transplantation.</p>\n<p>The <strong>maximum dose</strong> of acetaminophen that can be given is <strong>4 g/day</strong>.&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Identify the correct match, regarding the drug and its adverse effect.",
    "choices": [
      {
        "id": 1,
        "text": "Hydralazine - heart failure"
      },
      {
        "id": 2,
        "text": "Atenolol - hemolytic anemia"
      },
      {
        "id": 3,
        "text": "Aliskiren - hypokalemia"
      },
      {
        "id": 4,
        "text": "Verapamil - constipation"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p>The correct match is <strong>verapamil</strong> causes <strong>constipation</strong>.</p>\n<p>Verapamil is a calcium channel blocker used for the treatment of paroxysmal supraventricular tachycardia, atrial fibrillation, and atrial flutter. Bradycardia and <strong>constipation</strong> are the important side effects of verapamil.</p>\n<p>Other options:</p>\n<p>Option A: <strong>Hydralazine</strong> is a <strong>vasodilator</strong> used in the treatment of&nbsp;heart failure, and <strong>hypertensive emergencies</strong>, especially preeclampsia.&nbsp;The drug is used&nbsp;as a combination pill containing isosorbide dinitrate (<strong>BiDil</strong>) in the treatment of heart failure. The important side effect of hydralazine is <strong>drug-induced lupus</strong>.</p>\n<p>Option B: <strong>Atenolol</strong> is a <strong>cardioselective beta-1 blocker</strong> used in the treatment of angina and hypertension. Atenolol doesn't cause <strong>hemolytic anemia</strong>.</p>\n<p>Option C: <strong>Aliskiren</strong> is a <strong>direct renin inhibitor</strong> used as an alternative&nbsp;<strong>antihypertensive</strong> drug for those who do not respond or do not tolerate 1st line drugs. The side effect of aliskiren is <strong>hyperkalemia</strong> and not hypokalemia.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A lady who had undergone mastectomy for breast cancer is being treated with tamoxifen. How long should it be stopped for before she can conceive?",
    "choices": [
      {
        "id": 1,
        "text": "1 month"
      },
      {
        "id": 2,
        "text": "3 months"
      },
      {
        "id": 3,
        "text": "No need to stop"
      },
      {
        "id": 4,
        "text": "Can be stopped and conceived soon after stopping"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>In a post-mastectomy patient undergoing therapy with <strong>tamoxifen</strong>, it should be <strong>stopped</strong> <strong>for</strong> <strong>3 months</strong> before she can <strong>conceive</strong>.</p>\n<p><strong>Tamoxifen</strong>&nbsp;is a selective estrogen receptor modulator&nbsp;<strong>(SERM)</strong>&nbsp;and is used as a chemotherapeutic agent in&nbsp;<strong>receptor positive breast cancer&nbsp;</strong>patients to prevent recurrence after surgery. It is the drug of choice in&nbsp;<strong>pre-menopausal women.</strong>&nbsp;It has an agonistic action on the endometrium, leading to an&nbsp;<strong>increased risk</strong>&nbsp;of&nbsp;<strong>endometrial cancers</strong> (2 fold risk)<strong>.</strong>&nbsp;Hence, it is not used in post-menopausal women.</p>\n<p>It is <strong>contraindicated</strong> in <strong>pregnancy</strong> due to teratogenic effects such as <strong>craniofacial abnormalities&nbsp;</strong>and reproductive tract abnormalities. For the same reason, it has to be stopped for <strong>3 months</strong> (due to long half-life) prior to <strong>conceiving</strong>.&nbsp;It is also stopped during lactation as it is secreted in breast milk. Other complications of tamoxifen include deep vein thrombosis, pulmonary embolism, and hot flashes.</p>\n<p><strong>Other breast cancer risk reduction techniques:</strong></p>\n<ol>\n<li aria-level=\"1\"><strong>Lifestyle modification:</strong>&nbsp;Low-calorie diet, daily exercise, no smoking, no drinking, etc.</li>\n<li aria-level=\"1\">More&nbsp;<strong>frequent screening</strong>&nbsp;with mammogram +/- MRI</li>\n<li aria-level=\"1\">Chemoprevention<strong>:</strong>&nbsp;Preferred in women &gt;35 years of age in patients who are ER/PR positive. Given for 5-10 years.</li>\n<ul>\n<li aria-level=\"2\"><strong>SERMS</strong>&nbsp;(selective estrogen receptor modulators) - Tamoxifen and raloxifene. These have adverse effects.&nbsp;</li>\n<li aria-level=\"2\"><strong>Aromatase Inhibitors</strong>&nbsp;(AIs): They are used only in <strong>post-menopausal women.</strong></li>\n</ul>\n<li aria-level=\"1\"><strong>Risk-reduction surgeries:</strong>&nbsp;preferred in patients with&nbsp;<strong>BRCA1/2</strong>&nbsp;mutations&nbsp;or patients with first-degree relatives with breast cancers. Provides &gt;90% risk-reduction. preferred in patients who have completed their family.</li>\n<ul>\n<li aria-level=\"2\"><strong>Bilateral mastectomy</strong></li>\n<li aria-level=\"2\"><strong>Salpingo-oophorectomy:</strong>&nbsp;Best results when done &lt; 40 years of age.</li>\n</ul>\n</ol>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A young boy with a history of multiple blood transfusions presents with bone pain for the past 6 months.  A peripheral smear showed sickle-shaped RBCs. Which of the following drugs are not used in the treatment of his condition?",
    "choices": [
      {
        "id": 1,
        "text": "Bebtelovimab"
      },
      {
        "id": 2,
        "text": "Voxelotor"
      },
      {
        "id": 3,
        "text": "Hydroxyurea"
      },
      {
        "id": 4,
        "text": "L-glutamine"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Bebtelovimab</strong> is not used in the treatment of <strong>sickle cell disease</strong>. The clinical features of <strong>multiple blood transfusions</strong>, <strong>bone pain,</strong> and <strong>sickle cells</strong> on peripheral smear are suggestive of <strong>sickle cell disease</strong>.</p>\n<p>Bebtelovimab is the new monoclonal antibody used for the treatment of COVID-19. It&nbsp;works by binding to the <strong>spike protein</strong> of the COVID-19 virus. It has been found useful in reducing the risk of hospitalization or death.&nbsp;Bebtelovimab retains the activity against the <strong>omicron</strong> variant.</p>\n<p>Other options:</p>\n<p>Option B: <strong>Voxelotor</strong> is an inhibitor of&nbsp;<strong>hemoglobin S</strong> <strong>polymerase </strong>and<strong>&nbsp;stabilizer </strong>of sickle cell hemoglobin<strong> (HbS)</strong> that is used in the therapy of sickle cell disease.</p>\n<p>Option C:&nbsp;<strong>Hydroxyurea</strong> improves fetal haemoglobin <strong>(HbF)</strong> and is the primary drug for <strong>controlling HbS</strong> in sickle cell disease. Thus improving the oxygen-carrying capacity of the blood.&nbsp;Hydroxyurea also inhibits the enzyme <strong>ribonucleotide reductase (RNR)</strong>, which is a rate-limiting step in the biosynthesis of DNA. This property of hydroxyurea is used in the treatment of various cancers, and myeloproliferative disorders like chronic myelogenous leukemia, and polycythemia.</p>\n<p>Option D: <strong>L-glutamine</strong>&nbsp;is a naturally occurring amino acid with <strong>antioxidant properties</strong>. It&nbsp;increases the availability of reduced glutathione which may lessen oxidative damage in sickle red blood cells.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "The half-life of letrozole is:",
    "choices": [
      {
        "id": 1,
        "text": "45 hours"
      },
      {
        "id": 2,
        "text": "70 hours"
      },
      {
        "id": 3,
        "text": "90 hours"
      },
      {
        "id": 4,
        "text": "120 hours"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p>The half-life of <strong>letrozole</strong> is <strong>45 hours</strong>.</p>\n<p>Letrozole is a <strong>reversible aromatase inhibitor</strong>. It is a non-steroidal compound that inhibits the aromatization of estrogen thereby causing <strong>estrogen depletion</strong>. Letrozole is rapidly absorbed with 99.9% oral bioavailability and has a&nbsp;<strong>t&frac12;</strong> of around <strong>41 hours</strong>.</p>\n<p>Letrozole is used as the first-line drug for <strong>estrogen-positive</strong> breast cancer following mastectomy in post-menopausal women.</p>\n<p>Adverse effects of letrozole are due to the depletion of estrogen. The commonly seen adverse effects are <strong>hot flashes</strong>, <strong>vaginal dryness</strong>, nausea, diarrhea, dyspepsia, accelerated bone loss, and thinning of hair.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Identify the false statement about eicosanoids.",
    "choices": [
      {
        "id": 1,
        "text": "Synthesized from arginine"
      },
      {
        "id": 2,
        "text": "Synthesized from arachidonic acid"
      },
      {
        "id": 3,
        "text": "Prostaglandins have 5 carbon ring"
      },
      {
        "id": 4,
        "text": "Synthesized in platelets"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<div class=\"ng-star-inserted\">\n<div class=\"table-responsive font-weight-light answer-scroll ng-star-inserted\">\n<p>A false statement about eicosanoids is they are synthesized from arginine. <strong>Eicosanoids</strong> are synthesized from <strong>arachidonic acid </strong>(Option B)</p>\n<p><strong>Eicosanoids</strong> are the most universally distributed autocoids in the body. <strong>Prostaglandins, thromboxanes,&nbsp;</strong>and <strong>leukotrienes</strong> comprise eicosanoids. Every cell is capable of synthesizing one or more eicosanoids. <strong>Platelets</strong> primarily synthesize <strong>thromboxanes</strong> (Option D).</p>\n<p>Eicosanoids are synthesized from <strong>arachidonic acid</strong>. Arachidonic acid is derived from membrane phospholipids. The release of <strong>arachidonic acid</strong>&nbsp;(AA) from the membrane phospholipids is mainly mediated by <strong>phospholipase</strong> <strong>A.</strong></p>\n<p>AA is metabolized by <strong>cyclooxygenases</strong> to produce <strong>prostaglandins </strong>and <strong>lipoxygenases</strong> to produce <strong>leukotrienes</strong> and lipoxins.</p>\n<div class=\"ng-star-inserted\">\n<div class=\"table-responsive font-weight-light answer-scroll ng-star-inserted\">\n<p>Inhibitors of metabolism of arachidonic acid:</p>\n<ul>\n<li><strong>Corticosteroids</strong> cause inhibition of prostaglandin synthesis by inhibiting<strong> phospholipase A2. <br /></strong></li>\n<li>Non-steroidal anti-inflammatory (<strong>NSAIDs</strong>) drugs inhibit the synthesis of <strong>prostaglandins</strong> by inhibiting the enzyme cyclooxygenase.</li>\n<li><strong>Zileuton</strong> inhibits the enzyme lipoxygenase thereby decreasing the synthesis of <strong>leukotrienes</strong>.</li>\n</ul>\n<p>Chemically, all prostaglandins are considered to be derivatives of prostanoic acid, having&nbsp;a<strong> five-carbon ring&nbsp;</strong>(Option C).</p>\n<p>The image given below shows the synthesis of various eicosanoids from arachidonic acid:</p>\n</div>\n</div>\n</div>\n</div>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/796e4a43627f4b17b0530b4e3b118f9ex1280x2080.JPEG"
    ]
  },
  {
    "text": "The given diagram shows the steps in bacterial cell wall formation. Identify the site of action of beta-lactam antibiotics.",
    "choices": [
      {
        "id": 1,
        "text": "1"
      },
      {
        "id": 2,
        "text": "2"
      },
      {
        "id": 3,
        "text": "3"
      },
      {
        "id": 4,
        "text": "4"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Beta lactams</strong> act on <strong>step 4</strong> in the given image.</p>\n<p>Mechanism of action of beta-lactams: They are the <strong>cell wall synthesis inhibitor</strong>. The \u03b2-lactam antibiotics inhibit this last step in peptidoglycan synthesis. They inhibit the enzyme\u00a0<strong>transpeptidase</strong>\u00a0which is required for cross-linking of the peptidoglycan chain. Transpeptidases cleave the terminal <strong>D-alanine</strong> of the peptide chains and form cross-linkages between them. This cross-linking provides <strong>rigidity</strong> and stability to the cell wall.\u00a0 \u00a0</p>\n<p>Transpeptidases and other related proteins constitute <strong>penicillin-binding proteins(PBP)</strong> and, are located in the bacterial cell membrane. \u03b2-lactam antibiotics are <strong>bactericidal</strong>. This is because bacterias swell and burst due to deficient cell walls when they divide in the presence of \u03b2-lactam antibiotics. <strong>Penicillins, cephalosporins, monobactams</strong>, and <strong>carbapenems</strong> are examples of \u03b2-lactam antibiotics.</p>\n<p><strong>Gram-positive bacteria</strong> are more susceptible to \u03b2-lactam antibiotics than gram-negative because their cell wall is almost entirely made of peptidoglycan.</p>\n<p>Resistance to\u00a0\u03b2-lactam antibiotics develops due to the production of the<strong> beta-lactamase</strong> enzyme and the development of altered penicillin-binding proteins like in methicillin-resistant <em>Staphylococcus aureus</em> (<strong>MRSA</strong>). \u03b2-lactamases\u00a0inactivate \u03b2-lactam antibiotics by opening the \u03b2-lactam ring. This could be overcome by using drugs that\u00a0inhibit this enzyme. Examples of <strong>\u03b2-lactamase inhibitors</strong> are <strong>clavulanic acid</strong>, <strong>sulbactam</strong>, and <strong>tazobactam.</strong></p>\n<p>Other options:</p>\n<p>Option A: <strong>Fosfomycin</strong> inhibits <strong>step 1</strong> in the image. It inhibits the cytoplasmic enzyme<strong>\u00a0enol pyruvate transferase </strong>that catalyses the initial step in the bacterial cell wall and hence cell wall synthesis. It is used for the treatment of urinary tract infections.</p>\n<p>Option B: <strong>Bacitracin</strong> inhibits <strong>step 2</strong> in the image. It is a cell wall synthesis inhibitor that interferes with\u00a0<strong>dephosphorylation</strong> in the cycling of the <strong>lipid carrier</strong> which transfers\u00a0peptidoglycan subunits to the growing cell wall. It is only given for topical application because of its severe nephrotoxicity when given systemically.</p>\n<p>Option C: <strong>Vancomycin</strong> inhibits <strong>step 3</strong> in the image. It binds to the <strong>D-Ala-D-Ala terminus</strong> of the newly formed peptidoglycan pentapeptide. This <strong>prevents further elongation</strong> of <strong>the peptidoglycan</strong> and its cross-linking. It is used against MRSA and <em><strong>Clostridium difficile </strong></em>infection. <strong>Redman syndrome</strong> due to histamine release following infusion is an important side effect.</p>\n<p>Note: The FDA has approved the use of <strong>cefepime-enmetazobactam</strong>, a combination of a fourth-generation cephalosporin and beta-lactamase inhibitor for use in<strong> complicated UTI</strong>s (including pyelonephritis).</p>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/abc89b147ae645269bf56a6a300e37ea.JPEG"
    ],
    "explanation_images": []
  },
  {
    "text": "Phospholipase C acts via which of the following G protein-coupled receptors?",
    "choices": [
      {
        "id": 1,
        "text": "Gs"
      },
      {
        "id": 2,
        "text": "Gi"
      },
      {
        "id": 3,
        "text": "Gq"
      },
      {
        "id": 4,
        "text": "Go"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Phospholipase C</strong> acts via the&nbsp;<strong>Gq</strong> type of G protein-coupled receptors.</p>\n<p><strong>G protein-coupled receptors</strong> (GPCRs) are<strong>&nbsp;cell membrane receptors</strong>&nbsp;that span across the membrane 7 times. They also serve as receptors for various <strong>peptide hormones</strong>, neurotransmitters, amino acids, etc.</p>\n<p>Subtypes of GPCRs are distinguished by their alpha subunits. The important subtypes of GPCRs are Gs, Gp, <strong>Gq</strong>, and Go.</p>\n<p>GPCRs act via various second messengers.&nbsp;The important ones with their action on the effector are:</p>\n<ul>\n<li>Gs causes activation of adenylyl cyclase and results in Ca2+ channel opening.</li>\n<li>Gi causes inhibition of adenylyl cyclase and results in K+ channel opening.</li>\n<li>Go causes Ca2+ channel inhibition.</li>\n<li><strong>Gq</strong> causes activation of <strong>p</strong><strong>hospholipase C</strong>&nbsp;which generates the second messengers inositol 1,4,5-trisphosphate (<strong>IP3</strong>) and diacylglycerol (<strong>DAG</strong>). The&nbsp;water-soluble IP3 diffuses to the cytosol and mobilizes <strong>Ca2+</strong> from endoplasmic reticular depots.</li>\n</ul>\n<p>The given below image shows the effects of phospholipase C after activation by <strong>Gq</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/e96493e16a4840bbac92bc927f00f27dx1159x976.JPEG"
    ]
  },
  {
    "text": "A patient was diagnosed with pulmonary tuberculosis and was started on first-line antitubercular drugs. Which of the following drug acts by inhibiting the synthesis of the marked layer shown in the image?",
    "choices": [
      {
        "id": 1,
        "text": "Isoniazid"
      },
      {
        "id": 2,
        "text": "Rifampicin"
      },
      {
        "id": 3,
        "text": "Pyrazinamide"
      },
      {
        "id": 4,
        "text": "Ethambutol"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Isoniazid</strong> is the first-line antitubercular drug that acts by inhibiting the synthesis of&nbsp;<strong>mycolic acid</strong>.</p>\n<p><strong>Isoniazid</strong> is a first-line bactericidal drug that is used for the treatment of tuberculosis. This drug enters bacilli by <strong>passive diffusion</strong>. It then gets activated to its toxic form by the enzyme <strong>catalase-peroxidase</strong>(the enzyme encoded by the <strong>Kat gene</strong>).</p>\n<p>Normally, InhA and KasA are involved in the synthesis of mycolic acid. Upon activation, the reactive metabolite of isoniazid forms complexes with <strong>NAD</strong> that inhibit <strong>InhA</strong> and <strong>KasA</strong>. Hence, isoniazid inhibits the production of <strong>mycolic acid</strong>.</p>\n<p>The reactive isoniazid metabolite also forms complexes with <strong>NADP</strong>. This complex inhibits mycobacterial dihydrofolate reductase which results in the interruption of <strong>DNA synthesis</strong>.</p>\n<p>Side effects of isoniazid include:</p>\n<ul>\n<li><strong>Peripheral neuritis</strong> due to interference with the production of active coenzyme pyridoxal phosphate from pyridoxine. Therefore, <strong>pyridoxine 10mg/day (vitamin B6)</strong> is given prophylactically along with isoniazid to prevent neurotoxicity.</li>\n<li><strong>Hepatitis</strong> - isoniazid must be stopped at the first sign of hepatotoxicity.</li>\n<li>Rashes</li>\n<li>Anaemia</li>\n<li>Arthralgia</li>\n</ul>\n<p>Toxicity of isoniazid results in <strong>metabolic acidosis</strong>,&nbsp;<strong>seizures, and coma.</strong></p>\n<p>Other options:</p>\n<p>Option B:&nbsp;Rifampin acts by binding to <strong>DNA-dependent RNA polymerase</strong> to form a stable drug-enzyme complex. This complex suppresses RNA synthesis. Side effects of rifampin are hepatitis,<strong>&nbsp;flu-like illness, orange-red colored urine</strong>, and body secretions.</p>\n<p>&nbsp;Option C: Pyrazinamide is a prodrug, it is converted into an active metabolite<strong> pyrazinoic acid </strong>which makes the intracellular environment <strong>acidic</strong> and collapses the transmembrane proton motive force, thereby killing the bacteria. Side effects include&nbsp;<strong>hyperuricemia</strong> and hepatotoxicity.&nbsp;</p>\n<p>Option D: Ethambutol<strong> inhibits arabinose transferase III, </strong>thereby decreasing arabinogalactan biosynthesis<strong>. </strong>This results in&nbsp;disruption in&nbsp;mycobacterial cell wall synthesis.&nbsp;<strong>Optic neuritis</strong> is an important side effect of<strong> ethambutol</strong>. It results in decreased visual acuity and&nbsp;<strong>loss of red-green discrimination.</strong></p>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/ebe55c0cc99a42b383d1f16c8023a2ff.JPEG"
    ],
    "explanation_images": []
  },
  {
    "text": "A man was brought to the emergency room after poisoning with an unknown substance. Muscarinic poisoning was suspected and he was treated for the same. What is the possible presenting feature which led to the diagnosis?",
    "choices": [
      {
        "id": 1,
        "text": "Mydriasis"
      },
      {
        "id": 2,
        "text": "Diuresis"
      },
      {
        "id": 3,
        "text": "Muscle fasciculations"
      },
      {
        "id": 4,
        "text": "Bradycardia"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Bradycardia</strong> is the possible presenting feature which led to the diagnosis of <strong>muscarinic</strong> <strong>poisoning</strong>.</p>\n<p>Muscarinic poisoning occurs due to the consumption of <strong>poisonous mushroom</strong>-like <em>Inocybe</em>. <strong>Muscarinic symptoms</strong> appear within an hour of eating the mushroom. These symptoms (along with nicotinic symptoms) can also be seen in\u00a0<strong>organophosphate poisoning</strong>.</p>\n<p>There are <strong>5\u00a0subtypes</strong> of muscarinic receptors they are M<sub>1</sub>, M<sub>2</sub>, M<sub>3</sub>, M<sub>4</sub>, and M<sub>5</sub>. The effects exerted by the <strong>M receptors</strong> are given below:</p>\n<ul>\n<li>M<sub>1</sub>: Increased seizure activity.</li>\n<li>M<sub>2</sub>: <strong>Tremors</strong>, <span class=\"ILfuVd\" lang=\"en\"><span class=\"hgKElc\">bronchoconstriction,<strong> bradycardia</strong>, abdominal cramping</span></span><sub><br /></sub></li>\n<li>M<sub>3</sub>: Increased bladder contraction, <strong>miosis</strong>, increased salivary secretion</li>\n<li>M<sub>4</sub>: Cataplexy(sudden muscle weakness)</li>\n</ul>\n<p><strong>Atropine\u00a0</strong>is used for the management of muscarinic poisoning. It <strong>competitively </strong>blocks the acetylcholine at the muscarinic receptors.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 29-year-old lady came to psychiatry OPD with symptoms of hypomania. There is a past history of maniac episode. Now, she is planning to conceive.  Which drug should be avoided for being highly teratogenic to the fetus?",
    "choices": [
      {
        "id": 1,
        "text": "Valproate"
      },
      {
        "id": 2,
        "text": "Lithium"
      },
      {
        "id": 3,
        "text": "Oxcarbazepine"
      },
      {
        "id": 4,
        "text": "Olanzapine"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p>Option C:&nbsp;<strong>Oxcarbazepine </strong>was earlier associated with teratogenicity and fetal malformations, however, recent studies suggest that oxcarbazepine monotherapy during pregnancy does not carry a significant risk of fetal malformations.</p>\n<p>Option D:&nbsp;<strong>Olanzapine</strong>&nbsp;is an antipsychotic and an antimanic and it is not associated with&nbsp;teratogenicity.&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/52b96313ea0e49d49c0cf2421b8a135cx720x527.PNG",
      "https://dhmbxeygs57ff.cloudfront.net/uploads/c7d2d20a09874772b14772066b893f24x720x542.JPEG"
    ]
  },
  {
    "text": "True statement regarding the administration of 5 alpha-reductase inhibitors is/are:",
    "choices": [
      {
        "id": 1,
        "text": "1, 2, 3"
      },
      {
        "id": 2,
        "text": "1, 3, 4"
      },
      {
        "id": 3,
        "text": "1, 4"
      },
      {
        "id": 4,
        "text": "2, 3"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>True statements regarding the administration of <strong>5 alpha-reductase inhibitors</strong> are <strong>1,4</strong>. They reduce dihydrotestosterone levels and decrease prostate-specific antigen (PSA) levels.</p>\n<p>5 alpha-reductase inhibitors are the <strong>competitive</strong> inhibitors of the enzyme 5 \u03b1-reductase which converts testosterone into the more active dihydroxy testosterone (<strong>DHT</strong>). This enzyme inhibition results in:</p>\n<ul>\n<li><strong>Decreased DHT </strong>levels</li>\n<li><strong>Decreased PSA </strong>levels</li>\n<li>Reduces prostate volume</li>\n</ul>\n<p>However, plasma <strong>testosterone</strong> levels and\u00a0<strong>LH</strong> (luteinizing hormone) levels remain <strong>unchanged\u00a0</strong></p>\n<p><strong>Finasteride</strong> and <strong>dutasteride</strong> are the 5 \u03b1-reductase drugs currently in use. They are used in benign prostatic hyperplasia (<strong>BPH</strong>) along with surgery and adrenergic \u03b11 blockers for symptomatic relief. They can also be used in <strong>male pattern of baldness</strong> and hirsutism.</p>\n<p>Side effects of 5 \u03b1-reductase drugs are:</p>\n<ul>\n<li><strong>Impotence</strong></li>\n<li>Decreased libido</li>\n<li>Gynecomastia</li>\n<li>Skin rashes</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "The manufacturer of a drug company labels a drug as having 500 mg paracetamol. On quantitative analysis of the drug, it actually contained only 200 mg of paracetamol. What is this type of drug called?",
    "choices": [
      {
        "id": 1,
        "text": "Spurious drug"
      },
      {
        "id": 2,
        "text": "Adulterated drug"
      },
      {
        "id": 3,
        "text": "Unethical drug"
      },
      {
        "id": 4,
        "text": "Misbranded drug"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p>This type of drug is called a <strong>misbranded drug</strong>. A drug stating that 500mg of paracetamol is present in each tablet, but contains only 200mg is a&nbsp;<strong>misbranded</strong>&nbsp;<strong>drug</strong>, according to the <strong>Drugs and Cosmetics Act, 1940</strong> definition of misbranded drugs.</p>\n<p>According to the Drugs and Cosmetics act, 1940,&nbsp;a misbranded drug is a drug if its <strong>label</strong> or container or anything accompanying the drug bears any statement, design, or device which makes any <strong>false claim</strong> for the drug or which is false or misleading in any particular.</p>\n<p>Other options:</p>\n<p>Option A:&nbsp;<strong>Spurious drugs</strong>&nbsp;include drugs manufactured under&nbsp;<strong>another drug&nbsp;</strong>or<strong>&nbsp;manufacturer's name</strong>,&nbsp;<strong>imitations</strong>&nbsp;of other drugs, and drugs with labels from a&nbsp;<strong>fictitious company</strong>&nbsp;or individual. It also includes drugs substituted partly or wholly by another drug or substance.</p>\n<p>Option B:&nbsp;<strong>Adulterated drugs</strong>&nbsp;include those drugs that contain&nbsp;<strong>filthy</strong>, or decomposed&nbsp;<strong>substances</strong>, substances that are&nbsp;<strong>injurious to health</strong>, or if the drug harmful substances to&nbsp;<strong>reduce&nbsp;</strong>the<strong>&nbsp;quality&nbsp;</strong>or<strong>&nbsp;strength&nbsp;</strong>of the drug. It also includes drugs that were prepared in unsanitary conditions.</p>\n<p>Option C: The term&nbsp;unethical drug is not standard terminology in pharmacology. However, the term<strong> ethical drug </strong>is sometimes used to describe those <strong>drugs</strong> that are available <strong>only by prescription</strong> of a medical practitioner.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following anti-diabetic drugs is associated with the increased risk of fractures?",
    "choices": [
      {
        "id": 1,
        "text": "Rosiglitazone"
      },
      {
        "id": 2,
        "text": "Liraglutide"
      },
      {
        "id": 3,
        "text": "Voglibose"
      },
      {
        "id": 4,
        "text": "Canagliflozin"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Canagliflozin</strong> is associated with an increased risk of <strong>fractures</strong>.&nbsp;</p>\n<p>Canagliflozin is a <strong>sodium-glucose transporter-2 </strong>(SGLT2) inhibitor. SGLT2 is a Na+-glucose <strong>cotransporter</strong> that is located in the <strong>proximal convoluted tubule</strong>. They reabsorb glucose and sodium from the tubular lumen back into the blood through the epithelial cells. SGLT2 inhibitors block the transport of glucose&nbsp;in the proximal tubule and promote <strong>glycosuria</strong> and hence,&nbsp;lowering blood glucose.</p>\n<p>The currently available SGLT2 inhibitors are canagliflozin, dapagliflozin, and empagliflozin. Other than decreasing blood glucose they also decrease&nbsp;blood pressure and,&nbsp;cause <strong>weight loss</strong> of 2&ndash;4 kg. Empagliflozin and canagliflozin reduce the risk for major cardiovascular events.</p>\n<p>The main side effect of SGLT2 inhibitors is an increase in <strong>lower urinary tract infections</strong> and&nbsp;genital mycotic infections. This is because of their glycosuric properties. A recent warning from the FDA says that SGLT2 inhibitors may increase the risk of <strong>fractures</strong>. They also<strong>&nbsp;</strong>affect&nbsp;circulating levels of parathyroid hormone, and 1,25-hydroxy vitamin D thereby affecting&nbsp;the mineral balance in bone.</p>\n<p>Other options:</p>\n<p>Option A: <strong>Rosiglitazone</strong> is a thiazolidinedione that acts as a peroxisome proliferator-activated receptor &gamma; agonist in the adipose tissue which increases insulin sensitivity and adipose differentiation. Side effects are <strong>weight gain, edema,&nbsp;</strong>and<strong> increased risk of fractures.</strong>&nbsp;Compared to rosiglitazone, canagliflozin is commonly used in clinical practice. American diabetes association recommends canagliflozin as the first-line drug along with metformin, in patients with a high risk of cardiovascular disease, renal failure, and heart failure. Even when thiazolidinediones are required, clinicians prefer pioglitazone over rosiglitazone due to the higher risk of cardiovascular-related mortality in rosiglitazone. Therefore, <strong>canagliflozin</strong> would be a <strong>better</strong> option compared to rosiglitazone.&nbsp;</p>\n<div class=\"ng-star-inserted\">\n<div class=\"table-responsive font-weight-light answer-scroll ng-star-inserted\">\n<p>Option B: <strong>Liraglutide</strong> is a long-acting glucagon-like peptide-1 agonist. Nausea, diarrhea, and <strong>acute pancreatitis</strong> are some frequent side effects.</p>\n</div>\n</div>\n<p>Option C: <strong>Voglibose</strong> reduces the intestinal absorption of starch, dextrin, and disaccharides by inhibiting the action of<strong> &alpha;-glucosidase </strong>in the intestinal brush border. The most prominent adverse effects are malabsorption, flatulence, diarrhea, and abdominal bloating.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "The active metabolite of cyclophosphamide is:",
    "choices": [
      {
        "id": 1,
        "text": "N - hydroxy cyclophosphamide"
      },
      {
        "id": 2,
        "text": "4 - hydroxy cyclophosphamide"
      },
      {
        "id": 3,
        "text": "4 - acetyl cyclophosphamide"
      },
      {
        "id": 4,
        "text": "N - acetyl cyclophosphamide"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The active metabolite of cyclophosphamide is&nbsp;<strong>4 - hydroxy cyclophosphamide.&nbsp;</strong></p>\n<p><strong>Cyclophosphamide&nbsp;</strong>is an <strong>alkylating agent</strong> with antitumor and <strong>immunosuppressant</strong> properties. It is used for many solid tumors. The important side effects are<strong> cystitis</strong> due to metabolite <strong>acrolein</strong> and <strong>bladder carcinoma</strong>.&nbsp;</p>\n<p><strong>Cystitis</strong> caused by cyclophosphamide is treated by&nbsp;systemic administration of <strong>mesna</strong> and by irrigating the bladder with <strong>acetylcysteine</strong>. Both these drugs contain &ndash;SH which detoxifies the toxic metabolites. Plenty of fluids and frequent bladder voiding are also helpful.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Urinary alkalinization will be most useful in toxicity of which of the following drugs?",
    "choices": [
      {
        "id": 1,
        "text": "Beta blockers"
      },
      {
        "id": 2,
        "text": "Calcium channel blockers"
      },
      {
        "id": 3,
        "text": "Acetaminophen"
      },
      {
        "id": 4,
        "text": "Aspirin"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p>Alkalinization of urine will be helpful in the removal of aspirin, which is a&nbsp;<strong>weakly acidic drug</strong>&nbsp;and is susceptible to<strong>&nbsp;ion trapping</strong> in the&nbsp;urine.</p>\n<p>Aspirin is a weak acid, with a <strong>pKa of 3.0</strong>.&nbsp;Drugs that are subjected to renal clearance are excreted into the urine by glomerular filtration and active tubular secretion. Nonionized compounds are reabsorbed more rapidly than ionized polar molecules. When the&nbsp;<strong>pH</strong>&nbsp;of the&nbsp;<strong>urine&nbsp;increases</strong>, more salicylate is in its ionized form at equilibrium. Hence, salicylic acid&nbsp;<strong>diffuses</strong>&nbsp;into the&nbsp;<strong>tubular lumen</strong>&nbsp;of the kidney. Urine alkalinization is recommended as a first-line treatment only for moderately severe salicylate poisoning that&nbsp;does not meet the criteria for hemodialysis.</p>\n<p>Alkalinization of the urine is achieved by administration of&nbsp;<strong>100&ndash;150 mEq</strong>&nbsp;of&nbsp;<strong>sodium bicarbonate</strong>&nbsp;in 1 L of 5% dextrose in water (D5W). It is infused intravenously&nbsp;at twice the maintenance fluid requirements.</p>\n<p>Alkalinization of urine is&nbsp;<strong>contraindicated</strong>&nbsp;in&nbsp;<strong>renal failure</strong>&nbsp;or if fluid administration may worsen&nbsp;<strong>pulmonary edema</strong>&nbsp;or congestive heart failure.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A hospital is conducting a study to check the efficacy of statins in multiple centers. There are 4-5 patients per center and half of the patients receive the drug and the other half receive the placebo. Neither the patients nor clinicians know which drug is being administered. What phase of the clinical trial describes the above scenario?",
    "choices": [
      {
        "id": 1,
        "text": "Phase 1"
      },
      {
        "id": 2,
        "text": "Phase 3"
      },
      {
        "id": 3,
        "text": "Phase 2"
      },
      {
        "id": 4,
        "text": "Phase 4"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<div class=\"page\" title=\"Page 108\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>A hospital conducting a <strong>double-blinded</strong> study in <strong>multiple centers</strong> to check the <strong>efficacy of statins</strong>&nbsp;describes <strong>phase 3</strong> of the clinical trial. A <strong>phase 2</strong> clinical trial is generally conducted at a <strong>few centers (2-4)</strong> by physicians.</p>\n<p><strong>Phase 3</strong> of a clinical trial is also known as a <strong>multisite trial</strong>. It is conducted on a <strong>large patient population</strong> (500&ndash;3000) by several physicians at <strong>multiple centers</strong>. This phase involves patients who have been diagnosed with the disease that the drug claims to treat. Its purpose is to <strong>confirm the efficacy </strong>of the newly developed drug in a larger population. Phase 3 is <strong>randomized</strong>, <strong>controlled</strong>, and may be <strong>blinded</strong>.</p>\n</div>\n</div>\n</div>\n</div>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient who is a known addict is brought to the hospital with the intoxication of an agent. An ocular examination shows the following finding. Which of the following is true regarding this condition?",
    "choices": [
      {
        "id": 1,
        "text": "This action can be reversed by phenylephrine."
      },
      {
        "id": 2,
        "text": "It cannot be reversed by levallorphan."
      },
      {
        "id": 3,
        "text": "It is caused by activation of the Edinger-Westphal nucleus."
      },
      {
        "id": 4,
        "text": "Tolerance develops due to long-term use."
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The given clinical scenario and the image showing a pin-point pupil (miosis) suggest&nbsp;<strong>opioid overdose</strong>. The true statement among those given is that it is caused by activation of the<strong> Edinger-Westphal nucleus.</strong></p>\n<p><strong>Edinger-Westphal nucleus</strong> is a part of the <strong>light reflex pathway </strong>and is&nbsp;located in the midbrain. This nucleus is responsible for causing <strong>pupillary constriction</strong> when the retina is exposed to light.&nbsp;</p>\n<p>Opioid overdose symptoms are a triad of coma, respiratory depression, and pinpoint pupils (miosis). Other features are hypotension, bradycardia, shallow breathing, and hypothermia.</p>\n<p><strong>Tolerance</strong>&nbsp;to miosis does not develop even in addicts who develop a high tolerance to opioids. Miosis is induced by all opioid agonists.</p>\n<p><strong>Naloxone&nbsp;</strong>is the drug of choice for opioid overdose.&nbsp;It<strong>&nbsp;</strong>is administered<strong>&nbsp;</strong>after adequate ventilation is established. <strong>Airway protection&nbsp;</strong>and&nbsp;<strong>ventilatory maintenance</strong>&nbsp;are the most important steps in the treatment of opioid overdose; this is because&nbsp;<strong>respiratory depression</strong>&nbsp;is the major cause of mortality in such cases.&nbsp;<strong>Single-dose</strong>&nbsp;<strong>activated charcoal</strong>&nbsp;can be administered if the opioid ingestion occurred within&nbsp;<strong>one hour</strong>.</p>\n<p><strong>Levallorphan</strong> is an <strong>opioid antagonist</strong>, with properties similar to those of <strong>naloxone</strong>. It can be used for <strong>opioid overdose</strong>. It reverses severe opioid-induced respiratory depression.</p>\n<p><strong>Phenylephrine</strong> is an <strong>&alpha;1-selective agonist</strong> that causes mydriasis,<strong>&nbsp;</strong>but it is not useful in the reversal of opioid-induced miosis.</p>",
    "explanation_video": "",
    "question_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/644ef3e20c3a40cd848cbccfa38d4188x1280x1006.JPEG"
    ],
    "explanation_images": []
  },
  {
    "text": "Match the following drugs in Column A with their contraindications in Column B.",
    "choices": [
      {
        "id": 1,
        "text": "A-1, B-3, C-2, D-4"
      },
      {
        "id": 2,
        "text": "A-4, B-1, C-3, D-2"
      },
      {
        "id": 3,
        "text": "A-2, B-4, C-1, D-3"
      },
      {
        "id": 4,
        "text": "A-3, B-2, C-4, D-1"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The correct answer is option B: A-4, B-1, C-3, D-2</p>\n<table style=\"height: 49px;\" width=\"415\">\n<tbody>\n<tr>\n<td style=\"width: 200.1px;\">A. Morphine</td>\n<td style=\"width: 200.1px;\">4. Head Injury</td>\n</tr>\n<tr>\n<td style=\"width: 200.1px;\">B. Amiodarone</td>\n<td style=\"width: 200.1px;\">1. QT prolongation</td>\n</tr>\n<tr>\n<td style=\"width: 200.1px;\">C. Vigabatrin</td>\n<td style=\"width: 200.1px;\">3. Pregnancy</td>\n</tr>\n<tr>\n<td style=\"width: 200.1px;\">D. Estrogen preparations</td>\n<td style=\"width: 200.1px;\">2. Thromboembolism</td>\n</tr>\n</tbody>\n</table>\n<p>In a patient with head injury, <strong>morphine</strong> is contraindicated because it <strong>increases intracranial tension</strong> due to CO\u2082 retention, precipitates <strong>respiratory depression,</strong> and may cause vomiting, miosis, and altered mental state which <strong>interferes with assessment</strong> of mental state.</p>\n<p><strong>Amiodarone</strong> should not be used in patients with <strong>prolonged QT interval</strong> because it may cause <strong>marked prolongation</strong> of the QT interval, bradycardia, and<strong> torsades de pointes</strong>.</p>\n<p><strong>Vigabatrin</strong>, an inhibitor of GABA-transaminase, an anti-convulsant, is contraindicated in pregnancy due to its potential <strong>teratogenic effect</strong>.</p>\n<p><strong>Estrogen preparations&nbsp;</strong>can contribute to the incidence and severity of <strong>t</strong><strong>hromboembolism,&nbsp;</strong>particularly if other risk factors are present. The risk of serious cardiovascular side effects is particularly marked in women more than 35 years of age who smoke heavily.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following statements is true regarding memantine?",
    "choices": [
      {
        "id": 1,
        "text": "1, 2, 3, 4"
      },
      {
        "id": 2,
        "text": "1, 2"
      },
      {
        "id": 3,
        "text": "3, 4"
      },
      {
        "id": 4,
        "text": "1, 2, 3"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>1 and 2</strong> are true statements regarding memantine.</p>\n<p>Memantine is a non-competitive&nbsp;<strong>NMDA receptor antagonist</strong>. It inhibits glutamate excitotoxicity. It delays the progression of dementia in<strong> Alzheimer's disease</strong>. Commonly, it is started in patients with <strong>moderate-to-severe</strong> disease.</p>\n<p>It can be given both as <strong>monotherapy</strong> or can be given <strong>along</strong> with <strong>cholinesterase inhibitors</strong>. It can be started at a dose of <strong>5 mg once daily</strong> and then progressively increased <strong>up to 10 mg twice daily</strong> for a minimum of 6 months.&nbsp;</p>\n<p>It can cause dizziness and headache. Since it is excreted in the kidney, careful dose adjustments should be made in patients with renal failure.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "The image below shows the life cycle of a virus. Which of the following drugs acts at step 5?",
    "choices": [
      {
        "id": 1,
        "text": "Raltegravir"
      },
      {
        "id": 2,
        "text": "Enfuvirtide"
      },
      {
        "id": 3,
        "text": "Tenofovir"
      },
      {
        "id": 4,
        "text": "Zidovudine"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p>Other options:</p>\n<p>Option B: Enfuvirtide acts at <strong>step 2</strong> in the given image. It blocks gp41 of the cell membrane and <strong>blocks the entry</strong> of the virus into the cell. It prevents the free viral particles from invading new CD4+ cells. It is effective against <strong>HIV-1.</strong></p>\n<p>Option C: Tenofovir acts at <strong>step 3</strong> in the given image. It is a nucleotide reverse transcriptase inhibitor (NRTI) that is effective against <strong>HIV-1,2</strong> and <strong>hepatitis B</strong> infections. It is used in adults and <strong>children &gt;2 years old. </strong>It can also be used for<strong> pre-exposure prophylaxis.&nbsp;</strong></p>\n<p>Option D: Zidovudine also acts at <strong>step 3</strong> in the given image. It is an NRTI and is effective against <strong>HIV-1,2</strong> and <strong>Human T-cell Lymphoma Virus (HTLV).</strong> It can be used in adults and children. It can also be used to prevent <strong>mother-to-child transmission.</strong></p>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/b656eec2969545cab6981b79ab874ed5.JPEG"
    ],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/61c1774501b74506af250308d493739ax850x704.PNG"
    ]
  },
  {
    "text": "Which of the following statements is correct regarding clinical trials?",
    "choices": [
      {
        "id": 1,
        "text": "New drug application is done after phase 4"
      },
      {
        "id": 2,
        "text": "Phase 4 is also called post-marketing surveillance"
      },
      {
        "id": 3,
        "text": "Phase 3 is always double-blinded"
      },
      {
        "id": 4,
        "text": "Phase 2 is done on healthy individuals"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Phase 4</strong> clinical trials are also called <strong>post-marketing surveillance&nbsp;</strong>is the correct statement.</p>\n<p>Other options:</p>\n<p>Option A: New drug application is done after <strong>phase 3</strong> of clinical trials.</p>\n<p>Option C:&nbsp;<strong>Phase 3</strong> trials <strong>may or may not be blinded</strong>.</p>\n<p>Option D:&nbsp;<strong>Phase 2</strong> trials are the first round of trials in <strong>patients</strong>. <strong>Phase 1</strong> trials are done in <strong>healthy</strong> volunteers.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Match the following teratogenic drugs with their teratogenic effects.",
    "choices": [
      {
        "id": 1,
        "text": "1-a, 2-b, 3-c, 4-d"
      },
      {
        "id": 2,
        "text": "1-c, 2-d, 3-a, 4-b"
      },
      {
        "id": 3,
        "text": "1-d, 2-a, 3-d, 4-c"
      },
      {
        "id": 4,
        "text": "1-d, 2-c, 3-b, 4-a"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p>The correctly matched pairs of teratogenic drugs and their effects is <strong>1-d, 2-c, 3-b, 4-a</strong>.</p>\n<p><span data-preserver-spaces=\"true\">Lithium use in early pregnancy causes <strong>Ebstein anomaly</strong> in the fetus. Fetal lithium exposure is associated with <strong>neonatal goiter</strong>, CNS depression, hypotonia (floppy baby syndrome), and cardiac murmur.</span></p>\n<p><strong>Gray baby syndrome </strong>occurs in neonates, especially premature ones, exposed to&nbsp;<strong>high doses of chloramphenicol&nbsp;</strong>(100 mg/kg), which are administered prophylactically.</p>\n<p><span data-preserver-spaces=\"true\"><strong>Fetal warfarin syndrome </strong>or<strong> warfarin embryopathy&nbsp;</strong>presents with&nbsp;</span><span data-preserver-spaces=\"true\">CNS abnormalities, <strong>d</strong></span><span data-preserver-spaces=\"true\"><strong>epressed nasal bridge</strong>/ saddle nose at birth, b</span><span data-preserver-spaces=\"true\">leeding diathesis, and g</span><span data-preserver-spaces=\"true\">rowth retardation. Hypoplasia of the nose, eye sockets, and long bones with stippling of epiphyses are also seen.</span></p>\n<p>Fetal thalidomide exposure causes phocomelia. This disorder is associated with <strong>underdeveloped limbs</strong> and <strong>absent pelvic bones.</strong> Both <strong>upper</strong> and <strong>lower</strong> limbs are <strong>affected</strong>, and a part of the limbs may be missing. Fused fingers and missing thumbs are also seen. Thalidomide was originally used for the treatment of <strong>pregnancy-associated morning sickness</strong> but was <strong>withdrawn</strong> due to this adverse effect.&nbsp;It re-entered the market for the treatment of erythema nodosum leprosum. It also has&nbsp;<strong>antiangiogenic</strong> and <strong>immunomodulatory</strong> effects.</p>\n<p>&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A young man sustained a scorpion sting 2 hours ago. On examination, his blood pressure is 108/ 60 mm Hg; HR, 72 beats/minute, and respiratory rate, 32 breaths/minute. He also complains of breathlessness. How do you manage this patient?",
    "choices": [
      {
        "id": 1,
        "text": "Metoprolol"
      },
      {
        "id": 2,
        "text": "Ivabradine"
      },
      {
        "id": 3,
        "text": "Prazosin"
      },
      {
        "id": 4,
        "text": "Frusemide"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The drug used to manage this condition is <strong>prazosin</strong> as it can counteract the effects of breathlessness most probably caused by pulmonary edema.</p>\n<p>The venom is a potent <strong>autonomic stimulator</strong> that causes the release of massive amounts of <strong>catecholamines</strong> from the adrenals. It also has a direct effect on the myocardium.</p>\n<p>It can present as <strong>neurotoxicity</strong> with restlessness or seizure-like activity, abnormal oculomotor function, and loss of pharyngeal muscle control that leads to respiratory compromise. Tongue fasciculations and hypersalivation are also common. <strong>Cardiovascular toxicity</strong> from systemic envenomation includes tachycardia, hypertension, pulmonary edema, and cardiogenic shock.</p>\n<p>If the scorpion has<strong> hemolytic</strong> venom, the reaction is mainly <strong>local</strong>, with edema, pain, and reddening. This usually lasts for one to two hours.&nbsp;</p>\n<p>Treatment:</p>\n<ul>\n<li>Pain - Paracetamol, NSAIDs, or opioids&nbsp;</li>\n<li>Sedation for agitation, oculomotor abnormalities, uncoordinated neuromuscular activity, and muscle spasms - <strong>Benzodiazepines</strong>&nbsp;</li>\n<li>Hypertension and<strong> pulmonary edema&nbsp;</strong>-&nbsp;<strong>Prazosin</strong> counteracts the adrenergic surge that can lead to these effects</li>\n<li>Cardiogenic shock - Antivenom, prazosin, nitroglycerin, dobutamine</li>\n<li>Cholinergic effects - Atropine</li>\n<li>Supportive care, wound care</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "An experiment is being conducted on a cat spine to study the effect of acetylcholine. The blood pressure is recorded at each intervention and is shown below. What does phase 4 in the graph indicate?",
    "choices": [
      {
        "id": 1,
        "text": "Muscarinic action of acetylcholine"
      },
      {
        "id": 2,
        "text": "Potentiation of acetylcholine"
      },
      {
        "id": 3,
        "text": "Antagonism of acetylcholine"
      },
      {
        "id": 4,
        "text": "Nicotinic action of acetylcholine"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p>Phase 4 in the graph indicates the <strong>nicotinic action</strong>&nbsp;of acetylcholine at<strong> higher doses</strong>.</p>\n<p>In phases 1 and 2, acetylcholine (Ach) acts on muscarinic receptors (at 2 micrograms and 50 micrograms) bringing down blood pressure. <strong>Atropine</strong> <strong>blocks</strong> the <strong>muscarinic receptor</strong>, so this action of acetylcholine is not seen in phase 3. However, in phase 4, <strong>higher doses</strong> of Ach (like 5 mg) act via the <strong>nicotinic receptor</strong>, shooting up the blood pressure. This phenomenon is called the reversal of Ach in blood pressure and was studied by Dale.&nbsp;</p>\n<p><strong>Nicotinic receptors</strong> are <strong>ligand-gated</strong> ion channels. It can be divided into two groups: muscle receptors (N<sub>M</sub>), which are found at the skeletal neuromuscular junction, and <strong>neuronal receptors</strong> (N<sub>N</sub>), which are found in the ganglia and CNS. When stimulated at higher doses, Ach acts on N<sub>N</sub>&nbsp;receptors, leading to the stimulation of <strong>sympathetic ganglia</strong> and <strong>adrenal medulla</strong>. This&nbsp;<strong>increases</strong> the heart rate, <strong>blood pressure</strong>, and myocardial contractility.</p>\n<p><strong>Muscarinic</strong> receptors are <strong>G-coupled protein</strong> receptors involved in the parasympathetic nervous system.&nbsp;M1, M2, M3, M4, and M5 are the receptor subtypes. They act via Gi or Gq subunits. When <strong>Ach</strong> is administered, it acts on&nbsp;muscarinic receptors, primarily the<strong> M3 receptors</strong>, which are located on <strong>vascular endothelial cells</strong>. It stimulates <strong>guanylyl cyclase</strong> and promotes relaxation via a cyclic GMP&ndash;dependent mechanism. At higher doses, it acts on&nbsp;<strong>M2 receptors,</strong> which have direct effects on the <strong>heart</strong>. It also inhibits the release of norepinephrine from sympathetic nerve terminals and decreases cyclic AMP levels.</p>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/2b3ddec429404fce9e5a9874a7a2d2f7.JPEG"
    ],
    "explanation_images": []
  },
  {
    "text": "A patient who is a known case of HIV is started on combined active antiretroviral therapy (cART). After 5 months of treatment, he develops hyperpigmentation in the palms and soles. What is the most likely drug causing this?",
    "choices": [
      {
        "id": 1,
        "text": "Nelfinavir"
      },
      {
        "id": 2,
        "text": "Emtricitabine"
      },
      {
        "id": 3,
        "text": "Abacavir"
      },
      {
        "id": 4,
        "text": "Zidovudine"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The most likely drug causing hyperpigmentation of the hands and soles would be <strong>emtricitabine.&nbsp;</strong></p>\n<p>Emtricitabine is an anti-retroviral drug that acts by <strong>inhibiting nucleoside reverse transcriptase</strong> (<strong>NRTI</strong>). It is well-tolerated and has minimal toxic effects. Adverse effects include <strong>hyperpigmentation</strong> of<strong>&nbsp;</strong>the <strong>skin</strong> (especially sun-exposed areas, palms, and soles), headache, vomiting, and nausea.</p>\n<p>Other options:</p>\n<p>Option A: Nelfinavir is a protease inhibitor that causes <strong>diarrhea</strong> or loose stools. It usually <strong>resolves within a month</strong> of starting the drug.&nbsp;</p>\n<p>Option C: Abacavir is an NRTI that can cause a life-threatening hypersensitivity syndrome. The syndrome presents with <strong>fever, abdominal pain,</strong> and&nbsp;<strong>maculopapular rash</strong>&nbsp;<strong>within 6 weeks</strong> of initiating abacavir. The drug must be immediately discontinued and must not be administered to the patient thereafter. Rarely, there might be respiratory and musculoskeletal side effects.&nbsp;</p>\n<p>Option D: Zidovudine is an NRTI that causes malaise, fatigue, myalgia, anorexia, and insomnia. Chronic use leads to <strong>nail hyperpigmentation</strong>. It can also cause bone marrow suppression.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Dorzolamide is a ______.",
    "choices": [
      {
        "id": 1,
        "text": "Topically applied sulfonamide antibacterial"
      },
      {
        "id": 2,
        "text": "Topical ocular carbonic anhydrase inhibitor"
      },
      {
        "id": 3,
        "text": "Second-generation sulfonylurea"
      },
      {
        "id": 4,
        "text": "Opioid receptor agonist"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Dorzolamide</strong> is a <strong>topical ocular carbonic anhydrase inhibitor</strong>.</p>\n<div class=\"page\" title=\"Page 462\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>It acts on carbonic anhydrase in the ciliary processes of the eye and mediates the formation of HCO<sub>3</sub><sup>-</sup><sub>&nbsp;</sub>in aqueous humor. Inhibition of carbonic anhydrase decreases the rate of formation of aqueous humor and consequently reduces intraocular pressure.</p>\n<div class=\"page\" title=\"Page 462\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>The major indication for carbonic anhydrase inhibitors is <strong>open-angle glaucoma</strong>. Dorzolamide and <strong>brinzolamide</strong>, which are available only as ophthalmic <strong>drops</strong>, are used for this purpose.</p>\n<p>Dorzolamide may be used for secondary glaucoma and in acute angle-closure glaucoma to lower intraocular pressure before surgery.</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient with erectile dysfunction is given sildenafil. The penile erectile function is found to be improved after the therapy. Which of the following mediates the action of sildenafil?",
    "choices": [
      {
        "id": 1,
        "text": "cAMP"
      },
      {
        "id": 2,
        "text": "cGMP"
      },
      {
        "id": 3,
        "text": "Calcium"
      },
      {
        "id": 4,
        "text": "Phosphatidyl glycerol and inositol phosphate"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Sildenafil </strong>is a<strong> phosphodiesterase 5 inhibitor </strong>and<strong>&nbsp;</strong>the<strong>&nbsp;</strong>action of the drug is mediated through<strong> cGMP</strong>. Erectile dysfunction&nbsp;is treated by phosphodiesterase-5&nbsp;(PDE-5) inhibitors like sildenafil, vardenafil, and tadalafil<strong>.&nbsp;</strong></p>\n<p>The corpus cavernosum produces nitric oxide during arousal that stimulates the formation of cGMP. cGMP causes relaxation of the smooth muscle of the corpus cavernosum and penile arteries, engorgement of the corpus cavernosum, and erection.&nbsp;</p>\n<p>The above-mentioned drugs<strong> compete</strong> for <strong>cyclic GMP</strong>, binding at the site of cyclic GMP hydrolysis on PDE5, enhancing the <strong>accumulation </strong>of<strong> cGMP&nbsp;</strong>and hence used in the management of erectile dysfunction. They are useful in treating pulmonary arterial hypertension.</p>\n<p><strong>Adverse effects</strong> of the drug are&nbsp;headache, flushing, nasal congestion, nasopharyngitis, and dyspepsia.&nbsp;Sildenafil and Vardenafil&nbsp;also cause <strong>retinal</strong> <strong>PDE-6 inhibition</strong> and can result in blurring of vision and <strong>blue-green tinting of the vision</strong>.</p>\n<p>&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Match the following diuretics in column A to their site of action in column B.",
    "choices": [
      {
        "id": 1,
        "text": "A-2, B-3, C-1, D-4"
      },
      {
        "id": 2,
        "text": "A-3, B-4, C-2, D-1"
      },
      {
        "id": 3,
        "text": "A-1, B-2, C-4, D-3"
      },
      {
        "id": 4,
        "text": "A-4, B-1, C-3, D-2"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p>The correct match is as follows:</p>\n<table style=\"height: 115px;\" width=\"348\">\n<tbody>\n<tr>\n<td style=\"width: 166.3px;\">Column A</td>\n<td style=\"width: 166.3px;\">Column B</td>\n</tr>\n<tr>\n<td style=\"width: 166.3px;\">A. Acetazolamide</td>\n<td style=\"width: 166.3px;\">4. Proximal convoluted tubule</td>\n</tr>\n<tr>\n<td style=\"width: 166.3px;\">B. Torsemide</td>\n<td style=\"width: 166.3px;\">1. Thick ascending loop of Henle</td>\n</tr>\n<tr>\n<td style=\"width: 166.3px;\">C. Chlorthalidone</td>\n<td style=\"width: 166.3px;\">3. Distal convoluted tubule</td>\n</tr>\n<tr>\n<td style=\"width: 166.3px;\">D. Vasopressin</td>\n<td style=\"width: 166.3px;\">2. Collecting duct</td>\n</tr>\n</tbody>\n</table>\n<p>&nbsp;</p>\n<p><strong>Acetazolamide,</strong> a <strong>carbonic anhydrase inhibitor,</strong> acts on the enzyme in epithelial cells of the <strong>proximal convoluted tubule.</strong> Acetazolamide is mainly used in patients with secondary glaucoma to reduce intra-ocular pressure, provide symptomatic relief in acute mountain sickness, and as treatment for absence seizures.</p>\n<p><strong>Torsemide,</strong> a loop diuretic, inhibits the Na<sup>+</sup>-K<sup>+</sup>-ATPase symporter in the <strong>thick ascending loop of Henle.</strong>&nbsp;It is used in <strong>acute pulmonary edema,</strong> edema associated with <strong>congestive cardiac failure, hypertension</strong> with renal insufficiency, and hyponatremia.</p>\n<p><strong>Chlorthalidone</strong>, a thiazide-like diuretic, inhibits the<strong> Na<sup>+</sup>-Cl<sup>-</sup> symporter</strong> in the <strong>distal convoluted tubule</strong>. It is used in&nbsp;<strong>hypertension and</strong>&nbsp;in&nbsp;<strong>edema</strong> associated with <strong>congestive cardiac failure, hepatic cirrhosis,</strong> nephrotic syndrome, and <strong>chronic renal failure</strong><strong>.</strong></p>\n<p><strong>Vasopressin</strong>, also known as <strong>anti-diuretic hormone</strong>, is secreted by the <strong>posterior pituitary</strong> and mainly acts on the <strong>collecting duct,</strong> and increases the <strong>reabsorption of water</strong> (anti-diuresis). Vasopressin or its agonists (such as desmopressin) are used in cases of <strong>diabetes insipidus</strong>, <strong>type I and type II von Willebrand's disease</strong>, primary nocturnal enuresis, and postoperative ileus.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Alkalinization of urine will be helpful in the removal of _____.",
    "choices": [
      {
        "id": 1,
        "text": "Weakly basic drugs"
      },
      {
        "id": 2,
        "text": "Strong electrolytes"
      },
      {
        "id": 3,
        "text": "Polar drugs"
      },
      {
        "id": 4,
        "text": "Weakly acidic drugs"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p>Alkalinization of urine will be helpful in the removal of <strong>weakly acidic drugs</strong> as they are susceptible to<strong>&nbsp;ion trapping</strong> in the&nbsp;urine.</p>\n<p>Drugs that are subjected to renal clearance are excreted into the urine by glomerular filtration and active tubular secretion. Nonionized compounds are reabsorbed more rapidly than ionized polar molecules. When the <strong>pH</strong> of the <strong>urine&nbsp;increases</strong>, more salicylate is in its ionized form at equilibrium. Hence, salicylic acid <strong>diffuses</strong> into the <strong>tubular lumen</strong> of the kidney. Urine alkalinization is recommended as a first-line treatment only for moderately severe salicylate poisoning that&nbsp;does not meet the criteria for hemodialysis.</p>\n<p>Alkalinization of the urine is achieved by administration of <strong>100&ndash;150 mEq</strong> of <strong>sodium bicarbonate</strong> in 1 L of 5% dextrose in water (D5W). It is infused intravenously&nbsp;at twice the maintenance fluid requirements.</p>\n<p>Alkalinization of urine is <strong>contraindicated</strong> in <strong>renal failure</strong> or if fluid administration may worsen&nbsp;<strong>pulmonary edema</strong> or congestive heart failure.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "All of the following side effects are more commonly seen with carbamazepine than oxcarbazepine, except_____.",
    "choices": [
      {
        "id": 1,
        "text": "Hypotension"
      },
      {
        "id": 2,
        "text": "Hyponatremia"
      },
      {
        "id": 3,
        "text": "Rash"
      },
      {
        "id": 4,
        "text": "Elevated levels of gamma glutamyl transpeptidases"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>Mechanism of action of some common antiepileptics:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Mechanism of action</strong></td>\n<td><strong>Antiepileptics</strong></td>\n</tr>\n<tr>\n<td>Sodium-channel blockers</td>\n<td>\n<p>Phenytoin</p>\n<p>Carbamazepine, Oxcarbazepine</p>\n<p>Eslicarbazepine</p>\n<p>Lamotrigine</p>\n<p>Topiramate</p>\n<p>Felbamate</p>\n<p>Valproate</p>\n<p>Rufinamide</p>\n<p>Levetiracetam</p>\n</td>\n</tr>\n<tr>\n<td>Calcium-channel blockers</td>\n<td>\n<p>Valproate</p>\n<p>Lamotrigine</p>\n<p>Ethosuximide</p>\n</td>\n</tr>\n<tr>\n<td>GABA<sub>A</sub>&nbsp;receptor modulators</td>\n<td>\n<p>Benzodiazepines</p>\n<p>Phenobarbital</p>\n<p>Felbamate</p>\n<p>Primidone</p>\n<p>Topiramate</p>\n<p>Carbamazepine, Oxcarbazepine</p>\n<p>Stiripentol</p>\n<p>Clobazam</p>\n</td>\n</tr>\n<tr>\n<td>\n<p class=\"p1\">GABA uptake inhibitors</p>\n</td>\n<td>\n<p class=\"p1\">Tiagabine</p>\n<p class=\"p1\">Vigabatrin</p>\n</td>\n</tr>\n<tr>\n<td>NMDA receptor antagonist</td>\n<td>Felbamate</td>\n</tr>\n<tr>\n<td>AMPA/Kainate receptor antagonist</td>\n<td>\n<p>Phenobarbital</p>\n<p>Topiramate</p>\n<p>Perampanel</p>\n</td>\n</tr>\n<tr>\n<td>HCN channel activity enhancers</td>\n<td>Lamotrigine</td>\n</tr>\n<tr>\n<td>Inhibitors of brain carbonic anhydrase</td>\n<td>\n<p>Acetazolamide</p>\n<p>Zonisamide</p>\n<p>Topiramate</p>\n</td>\n</tr>\n<tr>\n<td>Potassium-channel openers</td>\n<td>\n<p>Retigabine</p>\n<p>Topiramate</p>\n</td>\n</tr>\n</tbody>\n</table>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Match the following drugs with the targets of their actions.",
    "choices": [
      {
        "id": 1,
        "text": "A-2, B-3 , C-1 , D-4"
      },
      {
        "id": 2,
        "text": "A-4, B-3 , C-1 , D-2"
      },
      {
        "id": 3,
        "text": "A-3, B-4 , C-2 , D-1"
      },
      {
        "id": 4,
        "text": "A-4, B-3 , C-2 , D-1"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p>The correct pairs are as follows:</p>\n<table style=\"height: 121px; width: 271px;\">\n<tbody>\n<tr>\n<td style=\"width: 114.1875px;\">A. Trastuzumab&nbsp;</td>\n<td style=\"width: 142.8125px;\">4. HER2/neu</td>\n</tr>\n<tr>\n<td style=\"width: 114.1875px;\">B. Infliximab</td>\n<td style=\"width: 142.8125px;\">3.&nbsp; TNF &alpha;&nbsp;&nbsp;</td>\n</tr>\n<tr>\n<td style=\"width: 114.1875px;\">C. Sirolimus&nbsp;</td>\n<td style=\"width: 142.8125px;\">2.&nbsp;mTOR</td>\n</tr>\n<tr>\n<td style=\"width: 114.1875px;\">D. Imatinib</td>\n<td style=\"width: 142.8125px;\">1.&nbsp;BCR-ABL tyrosine kinase&nbsp;&nbsp;</td>\n</tr>\n</tbody>\n</table>\n<p>&nbsp;</p>\n<p><strong>Trastuzumab</strong> is a <strong>humanized monoclonal antibody against</strong>&nbsp;the external domain of <strong>HER2/neu</strong>. It&nbsp;is indicated as an adjuvant in the management of&nbsp;<strong>metastatic HER-2-positive breast cancer</strong>.</p>\n<div class=\"page\" title=\"Page 657\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Infliximab</strong> binds with high affinity to <strong>TNF-&alpha;</strong> and prevents the cytokine from binding to its receptors. Infliximab is used for the treatment of <strong>rheumatoid arthritis</strong>;&nbsp;it is used&nbsp;<strong>in combination with methotrexate</strong>&nbsp;in patients who do not respond to methotrexate alone. Infliximab is also used for the treatment of the symptoms of <strong>moderate-to-severe Crohn's disease</strong>.</p>\n</div>\n</div>\n</div>\n</div>\n<p><strong>Sirolimus</strong> is an antimetabolic and antiproliferative drug. It acts by forming a complex with an immunophilin called&nbsp;<strong>FKBP-12</strong>, which in turn inhibits the&nbsp;mammalian target of rapamycin (<strong>mTOR</strong>). mTOR is a protein kinase that blocks cell cycle progression at the G1 phase to S phase transition. It is used in the prophylaxis of organ transplant rejection.</p>\n<div class=\"page\" title=\"Page 1218\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Imatinib&nbsp;</strong>is a first-generation&nbsp;<strong>tyrosine kinase inhibitor. </strong>Imatinib attacks <strong>BCR-ABL translocation</strong>&nbsp;and is used in&nbsp;<strong>chronic myelocytic leukemia.</strong> It also inhibits c-kit and produces extended control of <strong>GI stromal tumors</strong>.</p>\n</div>\n</div>\n</div>\n</div>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient is brought with altered sensorium and seizures. Attender shows the laboratory report which reveals elevated transaminases. Which of the following can be used in this condition?",
    "choices": [
      {
        "id": 1,
        "text": "Midazolam"
      },
      {
        "id": 2,
        "text": "Diazepam"
      },
      {
        "id": 3,
        "text": "Alprazolam"
      },
      {
        "id": 4,
        "text": "Oxazepam"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Oxazepam&nbsp;</strong>can be used in patients with elevated transaminases. It is <strong>short-acting</strong>&nbsp;and so, can be used in patients with<strong> liver impairment</strong> or <strong>brain damage.</strong></p>\n<p>Oxazepam is an orally available benzodiazepine used to treat anxiety and alcohol withdrawal states. Hepatic oxidation is decreased in persons with liver disease and the elderly. Oxazepam and lorazepam&nbsp;undergo <strong>only</strong> <strong>hepatic glucuronidation</strong>.</p>\n<p>Other options:</p>\n<p>Option A:<strong> Midazolam</strong> is the <strong>benzodiazepine of choice</strong> for<strong> induction</strong> of anesthesia. The onset of anesthesia is within <strong>30 to 60</strong> seconds. It can also be used to control seizures, but there is <strong>no difference</strong> in the efficacy of intravenous midazolam and intravenous diazepam.</p>\n<p>Option B:<strong> Diazepam</strong> is a long-acting benzodiazepine. It is <strong>metabolized</strong> in the <strong>liver</strong> to active metabolites like nordazepam which are long-acting.&nbsp;Diazepam and its long-acting metabolites can <strong>accumulate</strong> significantly in <strong>elderly</strong> patients with <strong>liver disease</strong> and therefore should<strong> not</strong> be used in such cases.</p>\n<p>Option C:<strong> Alprazolam</strong>&nbsp;is metabolized by hepatic oxidation which is significantly decreased in liver impairment and elderly patients.</p>\n<p>&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "The lipid profile of a patient who suffered from acute coronary syndrome is given below. What drug can be used to treat this condition?",
    "choices": [
      {
        "id": 1,
        "text": "Fenofibrate 160 mg"
      },
      {
        "id": 2,
        "text": "Rosuvastatin + Fenofibrate"
      },
      {
        "id": 3,
        "text": "Rosuvastatin 10 mg"
      },
      {
        "id": 4,
        "text": "Atorvastatin 80 mg"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Atorvastatin 80 mg</strong> can be used to treat this condition.&nbsp;The first line of therapy in controlling cholesterol in patients with atherosclerotic cardiovascular disease (ASCVD) is starting a high-intensity statin. <strong>High-intensity statins</strong> include <strong>atorvastatin</strong> (40-80 mg) and <strong>rosuvastatin </strong>(20-40 mg)<strong>.</strong></p>\n<p>Statins are <strong>competitive inhibitors</strong> of <strong>HMG-CoA reductase</strong>. This leads to a decrease in cholesterol biosynthesis. Statins are also effective in reducing LDL and triglyceride levels.&nbsp;</p>\n<p>Other options:&nbsp;</p>\n<p>Option A. <strong>Fenofibrate</strong> reduces lipoprotein levels by interacting with Peroxisome proliferator-activated receptor (PPAR-&alpha;) and stimulating <strong>lipoprotein lipase</strong>. They are used as drugs of choice for treating hyperlipoproteinemia and severe hypertriglyceridemia (&gt;1000 mg/dL).</p>\n<p>Option B. <strong>Rosuvastatin and fenofibrate</strong> combination was previously used to reduce atherosclerotic cardiovascular disease risk. But recent studies have indicated no change in reduction and hence is <strong>not recommended anymore</strong>.&nbsp;</p>\n<p>Option C: <strong>Rosuvastatin 10 mg</strong> is a<strong> low-intensity statin</strong> and is mainly used for <strong>primary prevention</strong> against atherosclerotic cardiovascular disease.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "An anti-arrhythmic drug is shown to have the following effect. It is effective in both atrial and ventricular arrhythmias. Identify the drug.",
    "choices": [
      {
        "id": 1,
        "text": "Tocainide"
      },
      {
        "id": 2,
        "text": "Propranolol"
      },
      {
        "id": 3,
        "text": "Quinidine"
      },
      {
        "id": 4,
        "text": "Lignocaine"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>&nbsp;</p>\n<p>&nbsp;</p>\n<p>Option B:&nbsp;<strong>Propranolol</strong>&nbsp;is a&nbsp;<strong>&beta;-receptor-blocker </strong>and&nbsp;a<strong>&nbsp;class II antiarrhythmic.</strong></p>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/9a743f063aa049a4abcbf92fcafe7d5e.PNG"
    ],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/290d9cdbaa444b8590f4728bb58ece8fx1280x647.PNG",
      "https://dhmbxeygs57ff.cloudfront.net/uploads/e807614673e74d1abc58bf1072520068x1280x719.PNG",
      "https://dhmbxeygs57ff.cloudfront.net/uploads/222629548464450caaf40ff6f14c9debx1280x681.PNG"
    ]
  },
  {
    "text": "Which among the following is the false statement regarding statins?",
    "choices": [
      {
        "id": 1,
        "text": "Although HMG-CoA reductase inhibitors substantially reduce the risk of cardiovascular events, there is mild increase in lipoprotein a (Lpa) levels."
      },
      {
        "id": 2,
        "text": "These drugs should not be stopped even in severe conditions like injury, surgery, etc."
      },
      {
        "id": 3,
        "text": "They can be given with verapamil and other enzyme inhibitors."
      },
      {
        "id": 4,
        "text": "With the long term use, there is slight increase in the incidence of type 2 diabetes mellitus."
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The <strong>false</strong> statement regarding statins is that they&nbsp;<strong>can be given with verapamil and other enzyme inhibitors</strong>.</p>\n<p>Statins like atorvastatin and rosuvastatin are metabolized by the cytochrome 3A4 enzymes of the liver. <strong>Verapamil</strong> is a <strong>cytochrome 3A4 inhibitor</strong> and may interfere with statin degradation. This leads to an increase in serum statin levels. The most important feature of statin toxicity is myopathy. It can present as myalgia but can sometimes also lead to fatal <strong>rhabdomyolysis</strong>.&nbsp;</p>\n<p><strong>Statins</strong>&nbsp;are the most commonly used hypolipidemic drugs. Statins act by&nbsp;<strong>inhibiting</strong>&nbsp;the rate-limiting<strong>&nbsp;HMG-CoA reductase</strong>&nbsp;enzyme, which in turn&nbsp;<strong>inhibits cholesterol synthesis</strong>. They decrease levels of low-density lipoproteins (LDL) and triglycerides and increase the levels of high-density lipoproteins (HDL) in plasma.</p>\n<p>Other options:</p>\n<p>Option A:<strong> Lipoprotein (lp) a</strong> is an LDL molecule that has apolipoprotein b and an additional apolipoprotein a. Studies indicate that these molecules are atherogenic and may independently cause cardiovascular disease. Although <strong>HMG-CoA reductase inhibitors</strong> substantially reduce the risk of cardiovascular events, there is a mild <strong>increase</strong> in lipoprotein a levels.</p>\n<p>Option B: Statins can be continued during <strong>surgery</strong>. These drugs have proved to decrease overall mortality due to cardiovascular events. Statins also influence inflammatory responses and can be safely used in <strong>trauma.</strong></p>\n<p>Option D: Chronic administration of high statin doses also leads to an <strong>increased incidence</strong> of <strong>type 2 diabetes mellitus.</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Identify the drugs marked as A, B, and C.",
    "choices": [
      {
        "id": 1,
        "text": "A - Aspirin, B -Vorapaxar, C - Prasugrel"
      },
      {
        "id": 2,
        "text": "A - Aspirin, B - Eptifibatide, C - Vorapaxar"
      },
      {
        "id": 3,
        "text": "A - Aspirin, B - Eptifibatide, C - Prasugrel"
      },
      {
        "id": 4,
        "text": "A - Aspirin, B - Prasugrel, C - Eptifibatide"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The drugs marked A, B and C are <strong>aspirin</strong>, <strong>eptifibatide</strong>, and <strong>vorapaxar</strong>,<strong>&nbsp;</strong>respectively.</p>\n<p><strong>Aspirin</strong> causes inhibition of <strong>cyclooxygenase-1 (COX-1)</strong>,<strong>&nbsp;</strong>which would inhibit the formation of <strong>thromboxane A2</strong>. Thromboxane A2 is an inducer of platelet aggregation and is a potent vasoconstrictor. Hence, inhibition of its formation is responsible for antiplatelet action.</p>\n<p>Aspirin is a <strong>non-competitive, irreversible inhibitor</strong> of the cyclooxygenase (COX) enzyme. It is a <strong>nonselective COX inhibitor</strong> and inhibits both COX-1 and COX-2.&nbsp;</p>\n<p>Abciximab, tirofiban, and <strong>eptifibatide</strong> act by&nbsp;<strong>blocking Gp IIb/IIIa receptors</strong>. They are mainly used during&nbsp;<strong>percutaneous coronary intervention</strong>&nbsp;for acute coronary syndrome. They carry a&nbsp;<strong>high risk of bleeding</strong>&nbsp;and can cause&nbsp;<strong>thrombocytopenia</strong>.</p>\n<p><strong>Vorapaxar&nbsp;</strong>primarily inhibits platelet aggregation caused by&nbsp;<strong>thrombin.&nbsp;</strong>PAR-1 activation by thrombin contributes to platelet aggregation. Vorapaxar is a competitive antagonist of protease-activated receptor-1 (PAR-1). Vorapaxar is&nbsp;<strong>indicated in combination</strong>&nbsp;with aspirin and/or clopidogrel to reduce thromboembolic events in patients with MI or peripheral vascular disease.</p>\n<p><strong>Prasugrel&nbsp;</strong>is an<strong>&nbsp;irreversible P2Y12&nbsp;inhibitor </strong>and lasts for the entire lifetime of a platelet.</p>\n<div class=\"page\" title=\"Page 606\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Prasugrel is a&nbsp;<strong>prodrug</strong>&nbsp;that is used in patients with acute coronary syndrome who have undergone&nbsp;<strong>percutaneous coronary intervention.</strong>&nbsp;It<strong>&nbsp;reduces</strong>&nbsp;the rate of&nbsp;<strong>thrombotic cardiovascular events</strong>&nbsp;in such patients.&nbsp;</p>\n</div>\n</div>\n</div>\n</div>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/1cdc3b043f0b47cbac9a11aee230237c.JPEG"
    ],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/672ca9540c3b4fe7b9d71a5ec95b1f1dx1280x1585.JPEG"
    ]
  },
  {
    "text": "Which of the following is false regarding disulfiram?",
    "choices": [
      {
        "id": 1,
        "text": "Only 3"
      },
      {
        "id": 2,
        "text": "1, and 3"
      },
      {
        "id": 3,
        "text": "1, 3, and 4"
      },
      {
        "id": 4,
        "text": "2, 3, and 4"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p>The wrong statement/s regarding disulfiram is only 3.</p>\n<p>Disulfiram is an <strong>irreversible inhibitor</strong> of both cytosolic and mitochondrial forms of <strong>aldehyde dehydrogenase.</strong>&nbsp;It is used in behavioral modification for alcohol de-addiction.&nbsp;The principle of action is <strong>aversive conditioning</strong> (not anti-craving).</p>\n<p>Disulfiram can be given only to <strong>highly motivated</strong> individuals. It should not be administered until the person has <strong>abstained</strong> from alcohol for <strong>at least 12 hours</strong>.&nbsp;The disulfiram-alcohol reaction may persist as long as 14 days after the last dose of disulfiram.</p>\n<p>Alcohol consumption during disulfiram therapy can lead to <strong>increased</strong> concentrations of <strong>acetaldehyde</strong>. This can cause aversive reactions, resulting in flushing, pulsating headache, throbbing pain in the head and neck, nausea, vomiting, rashes, <strong>respiratory difficulties</strong>, chest pain, and autonomic manifestations.</p>\n<p>Disulfiram is usually given in the dose of <strong>250 mg/day</strong> (range of 125&ndash;500 mg/day).</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "G6PD can manifest with which of the following drugs?",
    "choices": [
      {
        "id": 1,
        "text": "Primaquine"
      },
      {
        "id": 2,
        "text": "Chloroquine"
      },
      {
        "id": 3,
        "text": "Penicillin"
      },
      {
        "id": 4,
        "text": "Tetracycline"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p>Drugs that carry a risk of clinical hemolysis in persons with G6PD deficiency:</p>\n<table style=\"width: 494px; height: 420px;\">\n<tbody>\n<tr style=\"height: 53px;\">\n<td style=\"width: 159.36142px; height: 53px;\">\n<p><strong>CLASS</strong></p>\n</td>\n<td style=\"width: 319.470123px; height: 53px;\">\n<p><strong>DRUGS</strong></p>\n</td>\n</tr>\n<tr style=\"height: 54px;\">\n<td style=\"width: 159.36142px; height: 54px;\">\n<p>Antimalarials</p>\n</td>\n<td style=\"width: 319.470123px; height: 54px;\">\n<p><strong>Primaquine &gt;&nbsp;</strong><strong>Chloroquine</strong></p>\n<p>Dapsone/chlorproguanil</p>\n</td>\n</tr>\n<tr style=\"height: 55px;\">\n<td style=\"width: 159.36142px; height: 55px;\">\n<p>Sulphonamides/sulphones</p>\n</td>\n<td style=\"width: 319.470123px; height: 55px;\">\n<p><strong>Sulfamethoxazole</strong></p>\n<p>Sulfasalazine, Sulfisoxazole</p>\n</td>\n</tr>\n<tr style=\"height: 20px;\">\n<td style=\"width: 159.36142px; height: 20px;\">\n<p>Antibacterial/antibiotics</p>\n</td>\n<td style=\"width: 319.470123px; height: 20px;\">\n<p><strong>Cotrimoxazole,&nbsp;</strong>Ciprofloxacin, Chloramphenicol, Nalidixic acid, Norfloxacin,&nbsp;<strong>Nitrofurantoin</strong></p>\n</td>\n</tr>\n<tr style=\"height: 16px;\">\n<td style=\"width: 159.36142px; height: 16px;\">\n<p>Others</p>\n</td>\n<td style=\"width: 319.470123px; height: 16px;\">\n<p>Naphthalene, Rasburicase&nbsp;</p>\n<p><strong>Methylene blue</strong></p>\n<p>&nbsp;</p>\n</td>\n</tr>\n</tbody>\n</table>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/4dc646e0a7344b62b2f3ad958aed8038x1279x914.JPEG",
      "https://dhmbxeygs57ff.cloudfront.net/uploads/1fed3123012943dd8852893c0cf05c83x1279x914.JPEG"
    ]
  },
  {
    "text": "Choose the correctly matched pairs regarding the drugs used in schizophrenia:",
    "choices": [
      {
        "id": 1,
        "text": "1,3"
      },
      {
        "id": 2,
        "text": "1,4"
      },
      {
        "id": 3,
        "text": "1,2,4"
      },
      {
        "id": 4,
        "text": "1,2,3,4"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The correct option regarding the drugs used to treat schizophrenia symptoms is <strong>option C</strong>.</p>\n<p>Drugs used to treat schizophrenia can be classified:</p>\n<ul>\n<li>Typical or 1st generation antipsychotics.</li>\n<li>Atypical or 2nd generation antipsychotics.</li>\n</ul>\n<p>All typical antipsychotics markedly <strong>improve positive symptoms</strong> of schizophrenia, which is attributed to their <strong>antagonism</strong> at&nbsp;the<strong> D<sub>2</sub> receptor</strong>. Some of the drugs included in this class are <strong>chlorpromazine</strong> and <strong>haloperidol.</strong></p>\n<p>Atypical antipsychotics are antagonists or inverse agonists at the 5HT<sub>2A</sub> receptor. <strong>5HT<sub>2A</sub> antagonism</strong> is responsible for <strong>reducing negative symptoms</strong> in schizophrenia. Some of the drugs that belong to this class are clozapine, aripiprazole, and brexpiprazole.</p>\n<p>Atypical antipsychotics have lower extrapyramidal symptoms as compared to typical antipsychotics as the former has a lesser affinity to the D2 receptor. <strong>Muscarinic antagonists</strong>&nbsp;can be given to decrease the extrapyramidal symptoms. For example, <strong>promethazine</strong> or <strong>hydroxyzine</strong> is given for acute muscular dystonia, which is a form of extrapyramidal symptoms.</p>\n<p><strong>5HT<sub>1A</sub> receptor antagonism</strong>,&nbsp;not agonism, has been found to reduce food intake and hence reduce body weight.</p>\n<div class=\"page\" title=\"Page 256\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Aripiprazole and brexpiprazole are atypical antipsychotics that have partial agonist effects at the 5HT<sub>1A</sub> receptor. They have been approved for the treatment of schizophrenia and as an adjunctive treatment for depression.</p>\n</div>\n</div>\n</div>\n</div>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient presented with a lesion, as shown in the image below. She is an immunocompromised patient currently on HAART. What are the systemic antifungal drugs that can be added along with the HAART in this patient?",
    "choices": [
      {
        "id": 1,
        "text": "Inj. Amphotericin B 4-8 weeks, followed by oral itraconazole"
      },
      {
        "id": 2,
        "text": "Inj. Amphotericin  B 8 weeks, followed by oral posaconazole"
      },
      {
        "id": 3,
        "text": "Inj. Fluconazole, followed by oral fluconazole"
      },
      {
        "id": 4,
        "text": "Inj. Amphotericin  B, followed by flucytosine"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<div class=\"ng-star-inserted\">\n<div class=\"table-responsive font-weight-light answer-scroll ng-star-inserted\">\n<p>Treatment of the infection includes 4 steps:</p>\n<ol>\n<li>Initiation of therapy <strong>(amphotericin</strong> <strong>B</strong>) as early as possible. Posaconazole can also be used in the management of this condition.</li>\n<li><strong>Surgical</strong> debridement</li>\n<li><strong>Reversal</strong> of underlying conditions and <strong>risk factors</strong></li>\n<li><strong>Treatment</strong> of underlying <strong>malignancy</strong> if present</li>\n</ol>\n<p><strong>Amphotericin B</strong>&nbsp;is a <strong>broad-spectrum antifungal</strong>.&nbsp;It&nbsp;binds to <strong>ergosterol</strong> in the fungal membrane and forms <strong>pores or channels</strong> in the<strong> fungal cell membrane</strong>. This allows the leakage of cytosolic molecules and ions, leading to a loss of membrane integrity.</p>\n<p>Other options:</p>\n<p>Option A: <strong>Itraconazole </strong>can be used for the treatment of <strong>chronic</strong> aspergillosis if there is <strong>resistance </strong>or<strong> failure of voriconazole</strong>.&nbsp;<span data-preserver-spaces=\"true\"><span class=\"s1\"><strong>Ketoconazole </strong>is used for both <strong>dermatophytosis</strong> and deep mycosis, but it has been replaced by <strong>itraconazole</strong>.</span></span></p>\n<p><span data-preserver-spaces=\"true\"><span class=\"s1\">Option C: <strong>Fluconazole </strong>is used for the treatment of <strong>candidiasis</strong>&nbsp;and cryptococcosis.</span></span></p>\n<p>Option D: <strong>Amphotericin B</strong>&nbsp;in combination with 5-flucytosine is used as&nbsp;<strong>induction treatment</strong> for <strong>cryptococcal meningitis.</strong>&nbsp;</p>\n</div>\n</div>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/b742dd38b7fe4bfb8634f08f18183953.JPEG"
    ],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/d2ce95171f29405e8b920760512c5d76x800x600.JPEG"
    ]
  },
  {
    "text": "A patient who is on treatment for hyperlipidemia develops gallstones. What is the mechanism of action of the causative drug that was given to this patient?",
    "choices": [
      {
        "id": 1,
        "text": "Inhibits HMG CoA reductase"
      },
      {
        "id": 2,
        "text": "Activates PPAR alpha"
      },
      {
        "id": 3,
        "text": "Binds to deoxycholic acid"
      },
      {
        "id": 4,
        "text": "Decreases VLDL"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The<strong> antilipidemic drugs</strong> likely to cause<strong> gallstones </strong>are the peroxisome proliferator-activated receptors (<strong>PPARs</strong>) that act by activating <strong>PPAR alpha.</strong></p>\n<p><strong>PPARs</strong> are a superfamily of nuclear receptors involved&nbsp;in the regulation of energy homeostasis and metabolic function.&nbsp;It has three subtypes:</p>\n<ul>\n<li>PPAR&alpha; - reduces triglyceride level&nbsp;</li>\n<li>PPAR&gamma; - causes insulin sensitization&nbsp;</li>\n<li>PPAR&delta; - enhances fatty acids metabolism</li>\n</ul>\n<p>Lipoprotein lipase (LPL) is a key enzyme in the degradation of VLDL. Fibrates bind to PPAR alpha and cause <strong>stimulation</strong> of <strong>lipoprotein lipase</strong> enzyme. Increased LPL synthesis enhances the clearance of triglyceride-rich lipoproteins. Additionally, fibrates also <strong>stimulate fatty acid oxidation</strong> and <strong>reduce</strong> the expression of <strong>apo C-III</strong> (inhibitor of lipolysis). All fibrates increase the lithogenicity of bile, thereby increasing the risk of gall stones</p>\n<p>Other options:&nbsp;</p>\n<table style=\"height: 531px; width: 498px;\">\n<tbody>\n<tr>\n<td style=\"width: 16.0156px;\"><span style=\"text-decoration: underline;\"><strong>Class</strong></span></td>\n<td style=\"width: 10px;\"><strong>HMG- CoA reductase inhibitors (statins)</strong></td>\n<td style=\"width: 70px;\"><strong>Niacin</strong></td>\n<td style=\"width: 10px;\"><strong>Bile acid-binding resins</strong></td>\n</tr>\n<tr>\n<td style=\"width: 16.0156px;\"><span style=\"text-decoration: underline;\"><strong>Examples</strong></span></td>\n<td style=\"width: 10px;\">\n<p class=\"p1\">Lovastatin, atorvastatin</p>\n</td>\n<td style=\"width: 70px;\">Niacin</td>\n<td style=\"width: 10px;\">\n<p>Colestipol, <br />colesevelam</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 16.0156px;\"><span style=\"text-decoration: underline;\"><strong>Mechanism of action</strong></span></td>\n<td style=\"width: 10px;\">\n<p class=\"p1\">Inhibits HMG-CoA reductase</p>\n</td>\n<td style=\"width: 70px;\">Decreases the production of VLDLs and the catabolism of HDLs</td>\n<td style=\"width: 10px;\">Binds to bile acids in the intestinal lumen and increases excretion.&nbsp;</td>\n</tr>\n<tr>\n<td style=\"width: 16.0156px;\"><span style=\"text-decoration: underline;\"><strong>Major effects on lipoprotein levels</strong></span></td>\n<td style=\"width: 10px;\">\n<p>Reduces LDL levels</p>\n</td>\n<td style=\"width: 70px;\">\n<ul>\n<li>Reduces triglycerides,&nbsp; LDL, and lipoprotein a levels</li>\n<li>Significant <strong>increase HDL</strong> levels</li>\n</ul>\n</td>\n<td style=\"width: 10px;\">Reduces LDL levels&nbsp;</td>\n</tr>\n<tr>\n<td style=\"width: 16.0156px;\"><span style=\"text-decoration: underline;\"><strong>Important side effects</strong></span></td>\n<td style=\"width: 10px;\">\n<ul>\n<li><strong>Myopathy</strong></li>\n<li class=\"p1\">Elevations of serum amino-transferase activity</li>\n<li class=\"p1\">Elevation of creatine kinase activity</li>\n</ul>\n</td>\n<td style=\"width: 70px;\">\n<ul>\n<li>Cutaneous vasodilation</li>\n<li>Elevations in amino-transferases levels&nbsp;</li>\n</ul>\n</td>\n<td style=\"width: 10px;\">\n<ul>\n<li>Constipation</li>\n<li>Bloating&nbsp;</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table>\n<p>&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "The dose-response curve for three drugs in the same tissue is shown in the image below. Which of the following statements is true?",
    "choices": [
      {
        "id": 1,
        "text": "Efficacy of drug A is more than that of drug B."
      },
      {
        "id": 2,
        "text": "Potency of drug B is more than that of drug A."
      },
      {
        "id": 3,
        "text": "Drug A & drug B are agonists."
      },
      {
        "id": 4,
        "text": "Drug C is a non-competitive antagonist."
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>In the given image, <strong>drug A &amp; drug B are agonists.</strong>&nbsp;</p>\n<div class=\"page\" title=\"Page 53\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<div class=\"page\" title=\"Page 50\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Drugs that bind to physiological receptors and mimic the regulatory effects of endogenous signaling compounds' are <strong>agonists</strong>. Drugs that are only partially as effective as agonists are <strong>partial agonists</strong>.</p>\n<div class=\"page\" title=\"Page 53\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>The<strong> efficacy</strong> of a drug indicates the capacity of a drug to activate a receptor and <strong>generate a cellular response</strong>. A drug with high efficacy is a full agonist, eliciting a full response at some concentration. A drug with a low intrinsic efficacy will be a partial agonist. <strong>D</strong><strong>rug A &amp; drug B&nbsp;</strong>are <strong>agonists&nbsp;</strong>(Option C) that have the <strong>same efficacy&nbsp;</strong>(Option A), although, at different concentrations.</p>\n<p><strong>Drug C</strong> <strong>does not produce a full response</strong> at any concentration, making it a <strong>partial agonist</strong>. In the <strong>presence of a full agonist</strong>, a partial agonist behaves like a <strong>competitive antagonist</strong>&nbsp;(Option D).</p>\n<p>When two drugs produce equivalent responses, the drug whose dose-response curve lies to the left is said to be the more potent since it requires a lower dose to produce the same effect.&nbsp;<strong>Drug A</strong> &amp; <strong>drug</strong>&nbsp;<strong>B</strong> produce the same action and level of response in the tissue. The curve of drug A on the left indicates that it produces the<strong> same response</strong> at a <strong>lower concentration</strong>, making it <strong>more potent</strong> than drug B (Option B).</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/58ca7aff3ff64887b8cf57ae267880a1.JPEG"
    ],
    "explanation_images": []
  },
  {
    "text": "Which of the following drugs is a \u03b22 agonist?",
    "choices": [
      {
        "id": 1,
        "text": "1, 2, 3"
      },
      {
        "id": 2,
        "text": "4, 3, 2, 1"
      },
      {
        "id": 3,
        "text": "1, 2"
      },
      {
        "id": 4,
        "text": "3, 4"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Dipivefrine </strong>and<strong> dopexamine </strong>are&nbsp;&beta;<sub>2</sub>-adrenergic receptor agonists.</p>\n<p><strong>Dipivefrine</strong> causes a decrease in aqueous production and increases outflow. It was used in the treatment of<strong> open-angle glaucoma</strong> and<strong> ocular hypertension</strong>&nbsp;but has since been replaced.</p>\n<p><strong>Dopexamine</strong> is a synthetic analogue related to dopamine with activity at <strong>D1 </strong>and <strong>D2</strong> receptors as well as at <strong>&beta;2 receptors</strong>. It is used in patients with severe congestive heart failure, sepsis, and shock.</p>\n<p>Other options:</p>\n<p>B. <strong>Fenoldopam</strong> is a peripheral <strong>D1 agonist</strong> with moderate affinity for <strong>&alpha;2-adrenergic receptors</strong>. It is a rapidly acting <strong>vasodilator</strong> that is used in <strong>severe hypertension.</strong></p>\n<p>D. <strong>Mirabegron</strong> is a <strong>&beta;3-adrenergic receptor agonist</strong> which is used for <strong>bladder incontinence</strong>. Activation of this receptor in the bladder leads to detrusor muscle relaxation and increased bladder capacity. This action prevents voiding and provides relief for those with an overactive bladder and urinary incontinence.&nbsp;&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "What is the mechanism of action of sildenafil?",
    "choices": [
      {
        "id": 1,
        "text": "Inhibition of 5\u03b1-reductase"
      },
      {
        "id": 2,
        "text": "Inhibition of phosphodiesterase-5"
      },
      {
        "id": 3,
        "text": "Release of nitrous oxide radicals"
      },
      {
        "id": 4,
        "text": "Blockage of voltage-gated calcium channels"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Sildenafil </strong>acts by inhibiting <strong>phosphodiesterase-5&nbsp;</strong>(PDE-5)&nbsp;and is used in the treatment of <strong>erectile dysfunction.</strong></p>\n<p>PDE-5 inhibitors cause the accumulation of <strong>cGMP</strong> in the corpus cavernosum, which leads to the <strong>relaxation of smooth muscles of penile arteries</strong> that fill the corpus cavernosum, thereby improving erectile function in patients with erectile dysfunction.</p>\n<p>In addition to erectile dysfunction, sildenafil can be used in the treatment of <strong>pulmonary arterial hypertension</strong>.</p>\n<p>Adverse effects include <strong>headache, flushing,</strong> nasal congestion,&nbsp;<strong>blue-green tinting of vision</strong>,<strong>&nbsp;</strong>and erections lasting more than 4 hours.</p>\n<p>Sildenafil is <strong>contraindicated</strong> in patients using <strong>nitrate vasodilators,</strong>&nbsp;which could result in dangerously low blood pressure.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Choose the correct options regarding the route of administration and bioavailability.",
    "choices": [
      {
        "id": 1,
        "text": "A,B,D"
      },
      {
        "id": 2,
        "text": "A,C,D"
      },
      {
        "id": 3,
        "text": "A and C"
      },
      {
        "id": 4,
        "text": "A and D"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><span style=\"font-size: 14px;\">The correct option among the following is<strong> A, C, and D.</strong></span></p>\n<div class=\"page\" title=\"Page 61\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Bioavailability is defined as the <strong>fraction </strong>of a <strong>drug</strong> reaching<strong> systemic circulation </strong>in an&nbsp;unchanged form after administration by any route.<span style=\"font-size: 14px;\">&nbsp;The&nbsp;</span>area under the blood concentration-time curve (AUC)<span style=\"font-size: 14px;\"> is proportional to the dose and the extent of bioavailability for a drug.</span></p>\n</div>\n</div>\n</div>\n<p><strong>Bioavailability (F) = Quantity of drug reaching systemic circulation/Quantity of drug administered</strong></p>\n<p>Bioavailability depends on two factors, absorption and&nbsp;1st pass metabolism.&nbsp;The bioavailability of the drug&nbsp;<strong>injected intravenously</strong> is <strong>100%.</strong>&nbsp;But it is lower&nbsp;after <strong>oral ingestion</strong> because of&nbsp;incomplete absorption and first-pass&nbsp;metabolism in the intestinal wall or liver and lies between <strong>5% to &lt;100%</strong>. The bioavailability of&nbsp;<strong>subcutaneous </strong>and <strong>intramuscular </strong>routes lies between <strong>75% to&nbsp;<span style=\"font-size: 14px;\">&le;100%.</span></strong></p>\n<p>The image given below shows the difference between the bioavailability of drugs injected intravenously (IV) and administered per orally (PO). Note the area under the respective curves shaded in red and blue colors which represent the absorption of the drug.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/7548819eafdf43d6b3155642ccd9e678x1184x1162.PNG"
    ]
  },
  {
    "text": "A hypertensive patient on medication presents with the lab values as shown below. Which of the following drugs should be stopped?",
    "choices": [
      {
        "id": 1,
        "text": "Amlodipine"
      },
      {
        "id": 2,
        "text": "Metoprolol"
      },
      {
        "id": 3,
        "text": "Losartan"
      },
      {
        "id": 4,
        "text": "Furosemide"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>In this hypertensive patient with <strong>hyperkalemia</strong>, <strong>losartan</strong> must be stopped.</p>\n<p><strong>Losartan</strong>&nbsp;is competitive&nbsp;<strong>angiotensin I (AT1) receptor antagonist</strong>,&nbsp;which&nbsp;binds to the AT<sub>1</sub>&nbsp;receptor with high affinity. Uses of losartan are:</p>\n<ul>\n<li>Antihypertensive</li>\n<li>Renoprotective drug in diabetes mellitus</li>\n<li>Stroke prophylaxis</li>\n<li>Portal hypertension in cirrhosis without compromising renal function</li>\n<li>Anti-aggregant as it is a competitive antagonist of the thromboxane A2 receptor.</li>\n</ul>\n<p><strong>Hyperkalemia</strong>&nbsp;is an important side effect of ARBs.&nbsp;<span class=\"ILfuVd\" lang=\"en\"><span class=\"hgKElc\">Losartan appears to be a safe and efficacious agent to&nbsp;<strong>lower serum uric acid</strong>&nbsp;levels in patients with hyperuricemia.</span></span></p>\n<p>Option A: <strong>Gingival hyperplasia</strong>&nbsp;and&nbsp;<strong>ankle swelling</strong>&nbsp;are side effects of&nbsp;<strong>calcium channel blockers</strong>&nbsp;like&nbsp;<strong>amlodipine.</strong>&nbsp;Ankle edema occurs due to&nbsp;<strong>increased</strong>&nbsp;<strong>hydrostatic pressure</strong>&nbsp;in the capillaries present in the&nbsp;<strong>dependent parts</strong>&nbsp;of the body. This is due to&nbsp;<strong>reflex constriction</strong>&nbsp;of&nbsp;<strong>postcapillary vessels</strong>. Other common side effects of amlodipine include headache, dizziness, and abdominal pain.</p>\n<p>Option B: <strong>Metoprolol</strong>&nbsp;is a cardioselective beta blocker.<strong> Cardioselective</strong> beta blockers are <strong>less likely to cause hyperkalemia</strong> as an adverse effect. The risk of metoprolol-induced hyperkalemia is increased if the patient is also diabetic.</p>\n<p>Option D: <strong>Furosemide</strong>&nbsp;is a&nbsp;<strong>loop diuretic. </strong>It acts by&nbsp;<strong>inhibiting</strong>&nbsp;the<strong>&nbsp;Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup>&nbsp;symporter </strong>in the&nbsp;thick ascending limb&nbsp;of the&nbsp;loop&nbsp;of Henle&nbsp;resulting in increased<strong> excretion of sodium, potassium,</strong> and<strong> chloride</strong>.&nbsp;<strong>Hypokalemia, hyperuricemia, hypocalcemia</strong>, and hypomagnesemia are the important side effects.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following is the most effective oral drug in smoking cessation?",
    "choices": [
      {
        "id": 1,
        "text": "Varenicline"
      },
      {
        "id": 2,
        "text": "Cevimeline"
      },
      {
        "id": 3,
        "text": "Muscarine"
      },
      {
        "id": 4,
        "text": "Atropine"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Varenicline</strong> is the most effective oral drug for smoking cessation.</p>\n<p><strong>Nicotine</strong> is the principal constituent of tobacco responsible for its addictive behaviour.&nbsp;Varenicline works by blocking the effects of nicotine on the brain. It <strong>blocks</strong> <strong>&alpha;4</strong>, and<strong> &beta;2 nicotinic acetylcholine receptor</strong> subtypes and&nbsp;<strong>inhibits dopaminergic activation</strong> produced by smoking through their <strong>partial agonism. </strong>It&nbsp;decreases the craving and withdrawal syndrome that occurs with cessation attempts. It prevents nicotine stimulation of the mesolimbic dopamine system associated with nicotine addiction, thus helping to occlude the rewarding effect of smoking.</p>\n<p>Varenicline is prescribed only to patients <strong>18 years</strong> or older. It is taken <strong>orally</strong> and the dose taken is 0.5 mg once daily on days 1 to 3, increased to 0.5 mg twice daily on days 4 through 7, and 1 mg twice daily after day 8 for 11 weeks. Therapy should start one week before the target quit date. It can be continued for another 12 weeks (1 mg BD) to maintain abstinence.</p>\n<p>The adverse effects include nausea, disturbed sleep, sleepwalking, agitation, drowsiness, and constipation, and&nbsp;may also increase the risk of pancreatitis. Varenicline has also been implicated in specific skin syndromes such as <strong>Stevens-Johnson&nbsp;syndrome</strong>, erythema multiforme, and photosensitivity. Varenicline can cause renal failure and kidney stones, thus renal function must be monitored.</p>\n<p>The FDA has issued a warning about <strong>mood</strong> and <strong>behavioural changes</strong> associated with its use, and there is some evidence of <strong>increased cardiovascular risk.</strong></p>\n<p><strong>Cevimeline</strong><span data-preserver-spaces=\"true\">&nbsp;is a&nbsp;</span><strong><span data-preserver-spaces=\"true\">muscarinic agonist</span></strong><span data-preserver-spaces=\"true\">&nbsp;with an affinity for both&nbsp;</span><strong><span data-preserver-spaces=\"true\">M1</span></strong><span data-preserver-spaces=\"true\">&nbsp;and</span><strong><span data-preserver-spaces=\"true\">&nbsp;M3&nbsp;</span></strong><span data-preserver-spaces=\"true\">receptors on the lacrimal and salivary glands.&nbsp;</span><span data-preserver-spaces=\"true\">While&nbsp;</span><strong><span data-preserver-spaces=\"true\">M1 activation&nbsp;</span></strong>results in&nbsp;<strong><span data-preserver-spaces=\"true\">increased secretion</span></strong><span data-preserver-spaces=\"true\">,&nbsp;</span><strong><span data-preserver-spaces=\"true\">M3 activation&nbsp;</span></strong>results in<strong><span data-preserver-spaces=\"true\">&nbsp;smooth muscle contraction</span></strong><span data-preserver-spaces=\"true\">, and expulsion of the secretions.&nbsp;</span><span data-preserver-spaces=\"true\">Cevimeline enhances lacrimal secretions in&nbsp;</span><strong><span data-preserver-spaces=\"true\">Sjogren&rsquo;s syndrome.</span></strong></p>\n<p>&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Match the following antiarrhythmic drugs with their mechanism of action:",
    "choices": [
      {
        "id": 1,
        "text": "1-d, 2-b, 3-a, 4-c"
      },
      {
        "id": 2,
        "text": "1-a, 2-c, 3-d, 4-b"
      },
      {
        "id": 3,
        "text": "1-a, 2-d, 3-b, 4-c"
      },
      {
        "id": 4,
        "text": "1-d, 2-c, 3-a, 4-b"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The correct option is Option C:&nbsp;<strong>1-a, 2-d, 3-b, 4-c</strong></p>\n<p><strong>Quinidine </strong>is a<strong>&nbsp;class IA</strong> anti-arrhythmic agent. Class 1a agents are <strong>sodium channel blockers</strong> with significant potassium channel blocking properties. This slows conduction and <strong>prolongs the QRS duration </strong>and <strong>action potential duration</strong>.&nbsp;</p>\n<p><strong>Digoxin</strong> is a&nbsp;<strong>Na+ K+ ATPase inhibitor</strong> that works by increasing AV node refractoriness.</p>\n<p><strong>Esmolol</strong>&nbsp;is a&nbsp;<strong>&beta;-receptor-blocker </strong>and&nbsp;a<strong>&nbsp;class II antiarrhythmic.</strong></p>\n<p><strong>Ibutilide</strong> is a <strong>class III&nbsp;</strong>anti-arrhythmic agent. It works by <strong>blocking K+</strong> channels.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following drugs increases trabecular outflow?",
    "choices": [
      {
        "id": 1,
        "text": "Timolol"
      },
      {
        "id": 2,
        "text": "Netarsudil"
      },
      {
        "id": 3,
        "text": "Brimonidine"
      },
      {
        "id": 4,
        "text": "Acetazolamide"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The drug that increases trabecular outflow is <strong>netarsudil</strong>.</p>\n<p>Netarsudil is a <strong>rho-kinase inhibitor</strong> used in the treatment and management of <strong>glaucoma</strong> and ocular hypertension. It lowers the intra-ocular pressure directly through the relaxation of the <strong>trabecular meshwork</strong>, leading to an <strong>increase</strong> in <strong>aqueous outflow</strong>. It also reduces aqueous humor production.&nbsp;</p>\n<p>Netarsudil ophthalmic solution is instilled in <strong>one drop</strong> into the affected eye once daily in the <strong>evening</strong>. Adverse effects are conjunctival hyperemia, and <strong>corneal verticillata</strong>.</p>\n<p>Other options:</p>\n<p>Option A- Timolol is a <strong>non-selective&nbsp;&beta;-blocker</strong> that decreases the IOP by <strong>reducing</strong> the <strong>aqueous humor production</strong> through the blockade of the&nbsp;<strong>&beta;-receptors</strong> on the <strong>ciliary epithelium. </strong>Ocular adverse effects are allergy, decreased corneal sensation, and <strong>punctate keratitis.</strong></p>\n<p>Option C-&nbsp;<strong>Brimonidine</strong>&nbsp;is a <strong>selective alpha-2</strong> <strong>agonist&nbsp;</strong>which decreases aqueous synthesis and increases <strong>uveoscleral outflow</strong>. It can cross the blood-brain barrier and, hence, causes <strong>drowsiness and CNS depression</strong>. It is&nbsp;<strong>contraindicated</strong> in <strong>infants</strong> and <strong>children</strong>.</p>\n<p>Option D- <strong>Acetazolamide</strong> is a topical <strong>carbonic anhydrase inhibitor</strong> that decreases IOP by reducing <strong>aqueous formation</strong>. The main adverse effect is the <strong>bitter taste</strong> following administration. It is <strong>contraindicated</strong> in people with allergies to sulfonamide antibiotics.&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Finasteride is used to treat male-pattern baldness acts by inhibiting which of the following enzymes?",
    "choices": [
      {
        "id": 1,
        "text": "Aromatase"
      },
      {
        "id": 2,
        "text": "17-hydrolase"
      },
      {
        "id": 3,
        "text": "5-alpha reductase"
      },
      {
        "id": 4,
        "text": "Phosphodiesterase"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>Finasteride is used to treat male pattern baldness acts by inhibiting&nbsp;<strong>5-alpha reductase.</strong></p>\n<p>Finasteride&nbsp;is a competitive inhibitor of the&nbsp;5-alpha-reductase enzyme that<strong> inhibits the conversion</strong> of <strong>testosterone</strong> into its active form <strong>dihydrotestosterone</strong> (DHT).&nbsp;</p>\n<p>Finasteride inhibits <strong>type 2 5-alpha reductase</strong> within the hair follicle and reduces the production of DHT. Hence, it is used in the treatment of male pattern hair loss. But,&nbsp;<strong>new hair growth will be lost</strong> when finasteride is discontinued, similar to minoxidil.</p>\n<p>On long-term use (nearly 6 months), it produces an effect by <strong>reducing prostatic epithelial cell proliferation,&nbsp;</strong>thereby reducing the size of the prostate and improving urine flow.</p>\n<p>Adverse effects of finasteride:</p>\n<ul>\n<li>Decreased libido</li>\n<li>Erectile dysfunction</li>\n<li>Ejaculation disorder and decreased ejaculate volume</li>\n</ul>\n<p>Finasteride&nbsp;is <strong>highly teratogenic</strong> and<strong> pregnant women</strong> should not be exposed to the drug because of the <strong>potential for inducing genital abnormalities in male fetuses.</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Rituximab is a:",
    "choices": [
      {
        "id": 1,
        "text": "Polyclonal antibody which acts against CD20"
      },
      {
        "id": 2,
        "text": "Polyclonal antibody which acts against CD50"
      },
      {
        "id": 3,
        "text": "Monoclonal antibody which acts against CD20"
      },
      {
        "id": 4,
        "text": "Monoclonal antibody which acts against CD50"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<div class=\"page\" title=\"Page 942\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Rituximab</strong> is a&nbsp;<strong>monoclonal antibody</strong> that acts against<strong> CD20 B&shy;-cell antigen</strong> expressed on the surface of B&shy;-lymphocytes, plasma cells, and B&shy;-cell lymphomas.</p>\n<div class=\"page\" title=\"Page 943\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<div class=\"page\" title=\"Page 943\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>It promotes <strong>apoptosis</strong> through transmembrane signal&shy;ling as well as by <strong>antibody &shy;dependent</strong> and <strong>complement</strong>&shy; dependent cytotoxicity. It is used in the treatment of <strong>B&shy;-cell lymphoma</strong>, <strong>non-&shy;Hodgkin lymphoma,</strong> and <strong>chronic lymphocytic leukemia</strong>. It can be used both as a single agent as well as in combination with cyto&shy;toxic chemotherapy.</p>\n<div class=\"page\" title=\"Page 943\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<div class=\"page\" title=\"Page 943\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Adverse effects are infusion reactions like chills, fever, urticarial rashes, pruritus, dyspnea, and hypotension. Pretreatment with antihistaminics and corticosteroids prevents the reactions.</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A new drug application is filed after which phase of clinical trials?",
    "choices": [
      {
        "id": 1,
        "text": "4"
      },
      {
        "id": 2,
        "text": "3"
      },
      {
        "id": 3,
        "text": "2"
      },
      {
        "id": 4,
        "text": "1"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>New drug application is filed after<strong> phase 3 </strong>of clinical trials.</p>\n<p>Other options:</p>\n<p>Option A:&nbsp;<strong>Phase 4</strong> clinical trials are also called <strong>post-marketing surveillance.</strong></p>\n<p>Option C:&nbsp;<strong>Phase 2</strong> trials are the first round of trials in <strong>patients</strong>.</p>\n<p>Option D:&nbsp;<strong>Phase 1</strong> trials are done in <strong>healthy</strong> volunteers.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  }
];
        let quizName = '055 Pharmacology Ini-Cet 2022';
        let hierarchy = ["Marrow", "PYQs", "Pharmacology"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        const urlParams = new URLSearchParams(window.location.search);
        currentQuestionIndex = Math.min(parseInt(urlParams.get('startAt')) || 0, questionsData.length - 1);

        function goBack() {
            if (isQuizCompleted || confirm('Are you sure you want to leave the quiz? Your progress will be lost.')) {
                window.history.back();
            }
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                setTimeout(processAnswer, 300);
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            setTimeout(showSolution, 1500);
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }

            const audioContainer = document.getElementById('solutionAudio');
            audioContainer.innerHTML = '';
            if (question.explanation_audio_eng) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English Explanation:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
            }
            if (question.explanation_audio_hin) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish Explanation:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;
            }
            
            const imagesContainer = document.getElementById('solutionImages');
            imagesContainer.innerHTML = '';
            if (question.explanation_images) {
                 question.explanation_images.forEach(imgSrc => {
                    if(imgSrc) imagesContainer.innerHTML += `<div class="mt-4"><img src="${imgSrc}" alt="Explanation Image" class="w-full rounded-lg"></div>`;
                });
            }

            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';
                
                let audioHtml = '';
                if(question.explanation_audio_eng) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
                if(question.explanation_audio_hin) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;

                let imagesHtml = (question.explanation_images || []).map(src => src ? `<div class="mt-4"><img src="${src}" alt="Explanation Image" class="w-full rounded-lg"></div>` : '').join('');

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                        ${audioHtml}
                        ${imagesHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        function toggleSidebar() {
            document.getElementById('quizSidebar').classList.toggle('open');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (!window.location.pathname.endsWith('custom_quiz.html')) {
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>